Industries > Pharma > Antihypertensive Drugs Market Report 2021-2031
Antihypertensive Drugs Market Report 2021-2031
Forecasts By Drug (Diuretics, Angiotensin Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, Beta-blockers, Vasodilators, Calcium Channel Blockers, Renin Inhibitors, Alpha-blockers and Others), By Condition (Primary Hypertension and Secondary Hypertension), By Medication type (Monotherapy, Combination Therapy and Fixed Dose Combinations), By Drug Type (Generic Drugs and Branded Drugs), By Patient Demographics (Geriatric Patient, Adult Patient and Pediatric), By End-User (Hospitals, Homecare, Specialty Clinics and Others), By Distribution Channel (Hospital Pharmacy, Retail pharmacy, Ecommerce and Others), PLUS Profiles of Leading Manufacturing Companies and Regional and Leading National Market Analysis. PLUS COVID-19 Recovery Scenarios
Antihypertensive Drugs Market– our new study reveals trends, R&D progress, and predicted revenues
Where the Antihypertensive Drugs is market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2031, assessing data, trends, opportunities, and business prospects there.
Discover how to stay ahead
Our 200+ page report provides 450+ tables and 450+ charts/graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Antihypertensive Drugs Market. See how to exploit the opportunities.
Forecasts to 2031 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments.
Discover sales predictions for the world market and submarkets
Revenue and growth forecasts from 2021 to 2031 for the Global Antihypertensive Drugs Market By Drug
• Diuretics
o Thiazide Diuretics
o Loop Diuretics
o Potassium-sparing Diuretics
• Angiotensin Converting Enzyme Inhibitors
• Angiotensin Receptor Blockers
• Beta-blockers
o Beta-1 Selective
o Intrinsic Sympathomimetic
• Vasodilators
• Calcium Channel Blockers
• Renin Inhibitors
• Alpha-blockers
• Others
Revenue and growth forecasts from 2021 to 2031 for the Global Antihypertensive Drugs Market By Condition
• Primary Hypertension
• Secondary Hypertension
Revenue and growth forecasts from 2021 to 2031 for the Global Antihypertensive Drugs Market By Medication Type
• Monotherapy
• Combination Therapy
• Fixed Dose Combinations
Revenue and growth forecasts from 2021 to 2031 for the Global Antihypertensive Drugs Market By Drug Type
• Generic Drugs
• Branded Drugs
Revenue and growth forecasts from 2021 to 2031 for the Global Antihypertensive Drugs Market By Patient Demographics
• Geriatric Patient
• Adult Patient
• Pediatric
Revenue and growth forecasts from 2021 to 2031 for the Global Antihypertensive Drugs Market By End-User
• Hospitals
• Homecare
• Specialty Clinics
• Others
Revenue and growth forecasts from 2021 to 2031 for the Global Antihypertensive Drugs Market by Distribution Channel
• Hospital Pharmacy
• Retail pharmacy
• Ecommerce
• Others
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 20 leading national markets:
• North America
o U.S.
o Canada
• Europe
o Germany
o France
o United Kingdom
o Italy
o Spain
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o Australia
o South Korea
o Rest of Asia Pacific
• Latin America
o Brazil
o Mexico
o Argentina
o Rest of Latin America
• Middle East and Africa
o Turkey
o Saudi Arabia
o South Africa
o UAE
o Egypt
o Rest of Middle East and Africa
The report also includes profiles and for some of the leading companies in the Antihypertensive Drugs Market, with a focus on this segment of these companies’ operations.
Leading companies and the potential for market growth
Overall world revenue for Antihypertensive Drugs Market will surpass $xx million in 2021, our work calculates. We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How the Antihypertensive Drugs Market report helps you
In summary, our 500+ page report provides you with the following knowledge:
• Revenue forecasts to 2031 for Antihypertensive Drugs Market, with forecasts for Get our report today Antihypertensive Drugs Market Forecast 2021-2031: By Drug, Condition, Medication Type, Drug Type, Patient Demographics, End-User, Distribution Channel and Leading Regional/ Country market analysis each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues
• Revenue forecasts to 2031 for 5 regional and 16 key national markets – See forecasts for the Antihypertensive Drugs market in North America, Europe, Asia-Pacific and Rest of the World. Also forecasted is the market in the US, Canada, Argentina, Brazil, Germany, France, UK, Italy, Spain, China, India, Japan, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market– including company profiles for 15 of the major companies involved in the Antihypertensive Drugs Market. Some of the company’s profiled in this report include
• Pfizer Inc.
• Sanofi S.A
• Novartis AG
• Boehringer Ingelheim GmbH
• Actelion Ltd.
• F. Hoffmann-La Roche Ltd.
• Bayer AG
• Glenmark Pharmaceutical Inc.
• Daiichi Sankyo Company, Limited
• Takeda Pharmaceutical Company Limited
• AstraZeneca plc
• Johnson & Johnson Services, Inc.
• Lupin
• Merck & Co., Inc.
• Sun Pharmaceutical Industries Ltd.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
To access the data contained in this document please email contactus@visiongain.com
Buy our report today Antihypertensive Drugs Market Report 2021-2031: Forecasts By Drug (Diuretics, Angiotensin Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, Beta-blockers, Vasodilators, Calcium Channel Blockers, Renin Inhibitors, Alpha-blockers and Others), By Condition (Primary Hypertension and Secondary Hypertension), By Medication type (Monotherapy, Combination Therapy and Fixed Dose Combinations), By Drug Type (Generic Drugs and Branded Drugs), By Patient Demographics (Geriatric Patient, Adult Patient and Pediatric), By End-User (Hospitals, Homecare, Specialty Clinics and Others), By Distribution Channel (Hospital Pharmacy, Retail pharmacy, Ecommerce and Others), PLUS Profiles of Leading Manufacturing Companies and Regional and Leading National Market Analysis. PLUS COVID-19 Recovery Scenarios. Avoid missing out by staying informed – order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered By This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated Visiongain Reports
1.8. About Visiongain
2. Introduction to the Antihypertensive Drugs Market
2.1. Antihypertensive Drugs Market Definition
2.2. Application Submarkets Definitions
2.3. Component Submarkets Definitions
2.4. Condition Submarkets Definitions
3. Antihypertensive Drugs Market Overview
3.1. Global Antihypertensive Drugs Market Size and Forecast By Region
3.2. Global Antihypertensive Drugs Market Share By Region
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Increasing prevalence of hypertensive
3.3.1.2. Increasing strategic initiatives in antihypertensive drugs market
3.3.1.3. Increasing regulatory approvals in antihypertensive drugs market
3.3.1.4. Growing demand for antihypertensive drugs in emerging economies
3.3.2. Market Restraints/Challenges
3.3.2.1. Stringent regulation associated with product development
3.3.2.2. High cost of development
3.3.3. Opportunities
3.3.3.1. Increasing awareness program
3.3.3.2. Increasing therapeutic advancements in antihypertensive drugs
3.3.4. Challenges
3.3.4.1. Changing geopolitical scenario
3.3.4.2. Increasing number of player in the market
3.3.5. SWOT Analysis
3.3.5.1. Strengths
3.3.5.1.1. Strength 1
3.3.5.1.2. Strength 2
3.3.5.1.3. Strength 3
3.3.5.2. Weaknesses
3.3.5.2.1. Weakness 1
3.3.5.2.2. Weakness 2
3.3.5.2.3. Weakness 3
3.3.5.3. Opportunities
3.3.5.3.1. Opportunity 1
3.3.5.3.2. Opportunity 2
3.3.5.3.3. Opportunity 3
3.3.5.4. Threats
3.3.5.4.1. Threat 1
3.3.5.4.2. Threat 2
3.3.5.4.3. Threat 3
3.3.6. Porter’s Five Forces Analysis
3.3.6.1. Competitive Rivalry
3.3.6.2. Supplier Power
3.3.6.3. Buyer Power
3.3.6.4. Threat of Substitution
3.3.6.5. Threat of New Entry
4. Global Antihypertensive Drugs Market Analysis and Forecast 2021-2031, By Drug (Pre COVID and V, U, W and L COVID Recovery Scenarios)
4.1. Market Overview
4.1.1. Diuretics
4.1.1.1. Diuretics market size and forecast, 2021-2031 (USD Million)
4.1.2. Angiotensin Converting Enzyme Inhibitors
4.1.2.1. Angiotensin Converting Enzyme Inhibitors market size and forecast, 2021-2031 (USD Million)
4.1.3. Angiotensin Receptor Blockers
4.1.3.1. Angiotensin Receptor Blockers market size and forecast, 2021-2031 (USD Million)
4.1.4. Beta-blockers
4.1.4.1. Beta-blockers market size and forecast, 2021-2031 (USD Million)
4.1.5. Vasodilators
4.1.5.1. Vasodilators market size and forecast, 2021-2031 (USD Million)
4.1.6. Calcium Channel Blockers
4.1.6.1. Calcium Channel Blockers market size and forecast, 2021-2031 (USD Million)
4.1.7. Renin Inhibitors
4.1.7.1. Renin Inhibitors market size and forecast, 2021-2031 (USD Million)
4.1.8. Alpha-blockers
4.1.8.1. Alpha-blockers market size and forecast, 2021-2031 (USD Million)
4.1.9. Others
4.1.9.1. Others market size and forecast, 2021-2031 (USD Million)
5. Global Antihypertensive Drugs Market Analysis and Forecast, 2021-2031 By Condition (Pre COVID and V, U, W and L COVID Recovery Scenarios)
5.1. Market Overview
5.1.1. Primary Hypertension
5.1.1.1. Primary Hypertension market size and forecast, 2021-2031 (USD Million)
5.1.2. Secondary Hypertension
5.1.2.1. Secondary Hypertension market size and forecast, 2021-2031 (USD Million)
6. Global Antihypertensive Drugs Market Analysis and Forecast, 2021-2031 By Medication Type (Pre COVID and V, U, W and L COVID Recovery Scenarios)
6.1. Market Overview
6.1.1. Monotherapy
6.1.1.1. Monotherapy market size and forecast, 2021-2031 (USD Million)
6.1.2. Combination Therapy
6.1.2.1. Combination Therapy market size and forecast, 2021-2031 (USD Million)
6.1.3. Fixed Dose Combinations
6.1.3.1. Fixed Dose Combinations market size and forecast, 2021-2031 (USD Million)
7. Global Antihypertensive Drugs Market Analysis and Forecast, 2021-2031 By Drug Type (Pre COVID and V, U, W and L COVID Recovery Scenarios)
7.1. Market Overview
7.1.1. Generic Drugs
7.1.1.1. Generic Drugs market size and forecast, 2021-2031 (USD Million)
7.1.2. Branded Drugs
7.1.2.1. Branded Drugs market size and forecast, 2021-2031 (USD Million)
8. Global Antihypertensive Drugs Market Analysis and Forecast, 2021-2031 By Patient Demographics (Pre COVID and V, U, W and L COVID Recovery Scenarios)
8.1. Market Overview
8.1.1. Geriatric Patient
8.1.1.1. Geriatric Patient market size and forecast, 2021-2031 (USD Million)
8.1.2. Adult Patient
8.1.2.1. Adult Patient market size and forecast, 2021-2031 (USD Million)
8.1.3. Pediatric
8.1.3.1. Pediatric market size and forecast, 2021-2031 (USD Million)
9. Global Antihypertensive Drugs Market Analysis and Forecast, 2021-2031 By End-User (Pre COVID and V, U, W and L COVID Recovery Scenarios)
9.1. Market Overview
9.1.1. Hospitals
9.1.1.1. Hospitals market size and forecast, 2021-2031 (USD Million)
9.1.2. Homecare
9.1.2.1. Homecare market size and forecast, 2021-2031 (USD Million)
9.1.3. Specialty Clinics
9.1.3.1. Specialty Clinics market size and forecast, 2021-2031 (USD Million)
9.1.4. Others
9.1.4.1. Others market size and forecast, 2021-2031 (USD Million)
10. Global Antihypertensive Drugs Market Analysis and Forecast, 2021-2031 By Distribution Channel (Pre COVID and V, U, W and L COVID Recovery Scenarios)
10.1. Market Overview
10.1.1. Hospitals Pharmacy
10.1.1.1. Hospitals Pharmacy market size and forecast, 2021-2031 (USD Million)
10.1.2. Retail Pharmacy
10.1.2.1. Retail Pharmacy market size and forecast, 2021-2031 (USD Million)
10.1.3. Ecommerce
10.1.3.1. Ecommerce market size and forecast, 2021-2031 (USD Million)
10.1.4. Others
10.1.4.1. Others market size and forecast, 2021-2031 (USD Million)
11. North America Antihypertensive Drugs Market Analysis and Forecast, 2021-2031 Pre COVID and V, U, W and L COVID Recovery Scenarios)
11.1. Market Overview
11.2. North America Antihypertensive Drugs Market Size and Forecast By Drug
11.2.1.1. XX Driving/Opportunity Factor
11.2.1.2. XX Driving/Opportunity Factor
11.3. North America Antihypertensive Drugs Market Size and Forecast By Condition
11.3.1.1. XX Driving/Opportunity Factor
11.3.1.2. XX Driving/Opportunity Factor
11.4. North America Antihypertensive Drugs Market Size and Forecast By Medication Type
11.4.1.1. XX Driving/Opportunity Factor
11.4.1.2. XX Driving/Opportunity Factor
11.5. North America Antihypertensive Drugs Market Size and Forecast By Patient Demographics
11.5.1.1. XX Driving/Opportunity Factor
11.5.1.2. XX Driving/Opportunity Factor
11.6. North America Antihypertensive Drugs Market Size and Forecast By Drug Type
11.6.1.1. XX Driving/Opportunity Factor
11.6.1.2. XX Driving/Opportunity Factor
11.7. North America Antihypertensive Drugs Market Size and Forecast By End-User
11.7.1.1. XX Driving/Opportunity Factor
11.7.1.2. XX Driving/Opportunity Factor
11.8. North America Antihypertensive Drugs Market Size and Forecast By Distribution Channel
11.8.1.1. XX Driving/Opportunity Factor
11.8.1.2. XX Driving/Opportunity Factor
11.9. U.S. Antihypertensive Drugs Market
11.9.1.1. XX Driving/Opportunity Factor
11.9.1.2. XX Driving/Opportunity Factor
11.10. Canada Antihypertensive Drugs Market
11.10.1.1. XX Driving/Opportunity Factor
11.10.1.2. XX Driving/Opportunity Factor
12. Europe Antihypertensive Drugs Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
12.1. Market Overview
12.2. Europe Antihypertensive Drugs Market Size and Forecast By Drug
12.2.1.1. XX Driving/Opportunity Factor
12.2.1.2. XX Driving/Opportunity Factor
12.3. Europe Antihypertensive Drugs Market Size and Forecast By Condition
12.3.1.1. XX Driving/Opportunity Factor
12.3.1.2. XX Driving/Opportunity Factor
12.4. Europe Antihypertensive Drugs Market Size and Forecast By Medication Type
12.4.1.1. XX Driving/Opportunity Factor
12.4.1.2. XX Driving/Opportunity Factor
12.5. Europe Antihypertensive Drugs Market Size and Forecast By Patient Demographics
12.5.1.1. XX Driving/Opportunity Factor
12.5.1.2. XX Driving/Opportunity Factor
12.6. Europe Antihypertensive Drugs Market Size and Forecast By Drug Type
12.6.1.1. XX Driving/Opportunity Factor
12.6.1.2. XX Driving/Opportunity Factor
12.7. Europe Antihypertensive Drugs Market Size and Forecast By End-User
12.7.1.1. XX Driving/Opportunity Factor
12.7.1.2. XX Driving/Opportunity Factor
12.8. Europe Antihypertensive Drugs Market Size and Forecast By Distribution Channel
12.8.1.1. XX Driving/Opportunity Factor
12.8.1.2. XX Driving/Opportunity Factor
12.9. UK Antihypertensive Drugs Market
12.9.1.1. XX Driving/Opportunity Factor
12.9.1.2. XX Driving/Opportunity Factor
12.10. Germany Antihypertensive Drugs Market
12.10.1.1. XX Driving/Opportunity Factor
12.10.1.2. XX Driving/Opportunity Factor
12.11. France Antihypertensive Drugs Market
12.11.1.1. XX Driving/Opportunity Factor
12.11.1.2. XX Driving/Opportunity Factor
12.12. Rest of Europe Antihypertensive Drugs Market
12.12.1.1. XX Driving/Opportunity Factor
12.12.1.2. XX Driving/Opportunity Factor
13. Asia Pacific Antihypertensive Drugs Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
13.1. Market Overview
13.2. Asia-Pacific Antihypertensive Drugs Market Size and Forecast By Drug
13.2.1.1. XX Driving/Opportunity Factor
13.2.1.2. XX Driving/Opportunity Factor
13.3. Asia-Pacific Antihypertensive Drugs Market Size and Forecast By Condition
13.3.1.1. XX Driving/Opportunity Factor
13.3.1.2. XX Driving/Opportunity Factor
13.4. Asia-Pacific Antihypertensive Drugs Market Size and Forecast By Medication Type
13.4.1.1. XX Driving/Opportunity Factor
13.4.1.2. XX Driving/Opportunity Factor
13.5. Asia-Pacific Antihypertensive Drugs Market Size and Forecast By Patient Demographics
13.5.1.1. XX Driving/Opportunity Factor
13.5.1.2. XX Driving/Opportunity Factor
13.6. Asia-Pacific Antihypertensive Drugs Market Size and Forecast By Drug Type
13.6.1.1. XX Driving/Opportunity Factor
13.6.1.2. XX Driving/Opportunity Factor
13.7. Asia-Pacific Antihypertensive Drugs Market Size and Forecast By End-User
13.7.1.1. XX Driving/Opportunity Factor
13.7.1.2. XX Driving/Opportunity Factor
13.8. Asia-Pacific Antihypertensive Drugs Market Size and Forecast By Distribution Channel
13.8.1.1. XX Driving/Opportunity Factor
13.8.1.2. XX Driving/Opportunity Factor
13.9. China Antihypertensive Drugs Market
13.9.1.1. XX Driving/Opportunity Factor
13.9.1.2. XX Driving/Opportunity Factor
13.10. India Antihypertensive Drugs Market
13.10.1.1. XX Driving/Opportunity Factor
13.10.1.2. XX Driving/Opportunity Factor
13.11. Japan Antihypertensive Drugs Market
13.11.1.1. XX Driving/Opportunity Factor
13.11.1.2. XX Driving/Opportunity Factor
13.12. Rest of Asia Pacific Antihypertensive Drugs Market
13.12.1.1. XX Driving/Opportunity Factor
13.12.1.2. XX Driving/Opportunity Factor
14. Latin America Antihypertensive Drugs Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
14.1. Market Overview
14.2. Latin America Antihypertensive Drugs Market Size and Forecast By Drug
14.2.1.1. XX Driving/Opportunity Factor
14.2.1.2. XX Driving/Opportunity Factor
14.3. Latin America Antihypertensive Drugs Market Size and Forecast By Condition
14.3.1.1. XX Driving/Opportunity Factor
14.3.1.2. XX Driving/Opportunity Factor
14.4. Latin America Antihypertensive Drugs Market Size and Forecast By Medication Type
14.4.1.1. XX Driving/Opportunity Factor
14.4.1.2. XX Driving/Opportunity Factor
14.5. Latin America Antihypertensive Drugs Market Size and Forecast By Patient Demographics
14.5.1.1. XX Driving/Opportunity Factor
14.5.1.2. XX Driving/Opportunity Factor
14.6. Latin America Antihypertensive Drugs Market Size and Forecast By Drug Type
14.6.1.1. XX Driving/Opportunity Factor
14.6.1.2. XX Driving/Opportunity Factor
14.7. Latin America Antihypertensive Drugs Market Size and Forecast By End-User
14.7.1.1. XX Driving/Opportunity Factor
14.7.1.2. XX Driving/Opportunity Factor
14.8. Latin America Antihypertensive Drugs Market Size and Forecast By Distribution Channel
14.9. Brazil Antihypertensive Drugs Market
14.9.1.1. XX Driving/Opportunity Factor
14.9.1.2. XX Driving/Opportunity Factor
14.10. Mexico Antihypertensive Drugs Market
14.10.1.1. XX Driving/Opportunity Factor
14.10.1.2. XX Driving/Opportunity Factor
14.11. Rest of Latin America Antihypertensive Drugs Market
14.11.1.1. XX Driving/Opportunity Factor
14.11.1.2. XX Driving/Opportunity Factor
15. MEA Antihypertensive Drugs Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
15.1. Market Overview
15.2. MEA Antihypertensive Drugs Market Size and Forecast By Drug
15.2.1.1. XX Driving/Opportunity Factor
15.2.1.2. XX Driving/Opportunity Factor
15.3. MEA Antihypertensive Drugs Market Size and Forecast By Condition
15.3.1.1. XX Driving/Opportunity Factor
15.3.1.2. XX Driving/Opportunity Factor
15.4. MEA Antihypertensive Drugs Market Size and Forecast By Medication Type
15.4.1.1. XX Driving/Opportunity Factor
15.4.1.2. XX Driving/Opportunity Factor
15.5. MEA Antihypertensive Drugs Market Size and Forecast By Patient Demographics
15.5.1.1. XX Driving/Opportunity Factor
15.5.1.2. XX Driving/Opportunity Factor
15.6. MEA Antihypertensive Drugs Market Size and Forecast By Drug Type
15.6.1.1. XX Driving/Opportunity Factor
15.6.1.2. XX Driving/Opportunity Factor
15.7. MEA Antihypertensive Drugs Market Size and Forecast By End-User
15.7.1.1. XX Driving/Opportunity Factor
15.7.1.2. XX Driving/Opportunity Factor
15.8. MEA Antihypertensive Drugs Market Size and Forecast By Distribution Channel
15.8.1.1. XX Driving/Opportunity Factor
15.8.1.2. XX Driving/Opportunity Factor
15.9. GCC Antihypertensive Drugs Market
15.9.1.1. XX Driving/Opportunity Factor
15.9.1.2. XX Driving/Opportunity Factor
15.10. South Africa Antihypertensive Drugs Market
15.10.1.1. XX Driving/Opportunity Factor
15.10.1.2. XX Driving/Opportunity Factor
15.11. Rest of MEA Antihypertensive Drugs Market
15.11.1.1. XX Driving/Opportunity Factor
15.11.1.2. XX Driving/Opportunity Factor
16. Companies in the Antihypertensive Drugs Market
16.1. Pfizer Inc.
16.1.1. Company Snapshot
16.1.2. Company Overview
16.1.3. Financial Performance (2015-2019)
16.1.3.1. Net Revenue
16.1.3.2. Gross Profit
16.1.3.3. Geographical Revenue, 2019
16.1.4. Product Offerings
16.1.5. Recent Initiatives (2017-2019)
16.2. Sanofi S.A
16.2.1. Company Snapshot
16.2.2. Company Overview
16.2.3. Financial Performance (2015-2019)
16.2.3.1. Net Revenue
16.2.3.2. Gross Profit
16.2.3.3. Geographical Revenue, 2019
16.2.4. Product Offerings
16.2.5. Recent Initiatives (2017-2019)
16.3. Novartis AG
16.3.1. Company Snapshot
16.3.2. Company Overview
16.3.3. Financial Performance (2015-2019)
16.3.3.1. Net Revenue
16.3.3.2. Gross Profit
16.3.3.3. Geographical Revenue, 2019
16.3.4. Product Offerings
16.3.5. Recent Initiatives (2017-2019)
16.4. Boehringer Ingelheim GmbH
16.4.1. Company Snapshot
16.4.2. Company Overview
16.4.3. Financial Performance (2015-2019)
16.4.3.1. Net Revenue
16.4.3.2. Gross Profit
16.4.3.3. Geographical Revenue, 2019
16.4.4. Product Offerings
16.4.5. Recent Initiatives (2017-2019)
16.5. Actelion Ltd.
16.5.1. Company Snapshot
16.5.2. Company Overview
16.5.3. Financial Performance (2015-2019)
16.5.3.1. Net Revenue
16.5.3.2. Gross Profit
16.5.3.3. Geographical Revenue, 2019
16.5.4. Product Offerings
16.5.5. Recent Initiatives (2017-2019)
16.6. F. Hoffmann-La Roche Ltd.
16.6.1. Company Snapshot
16.6.2. Company Overview
16.6.3. Financial Performance (2015-2019)
16.6.3.1. Net Revenue
16.6.3.2. Gross Profit
16.6.3.3. Geographical Revenue, 2019
16.6.4. Product Offerings
16.6.5. Recent Initiatives (2017-2019)
16.7. Bayer AG
16.7.1. Company Snapshot
16.7.2. Company Overview
16.7.3. Financial Performance (2015-2019)
16.7.3.1. Net Revenue
16.7.3.2. Gross Profit
16.7.3.3. Geographical Revenue, 2019
16.7.4. Product Offerings
16.7.5. Recent Initiatives (2017-2019)
16.8. Glenmark Pharmaceutical Inc.
16.8.1. Company Snapshot
16.8.2. Company Overview
16.8.3. Financial Performance (2015-2019)
16.8.3.1. Net Revenue
16.8.3.2. Gross Profit
16.8.3.3. Geographical Revenue, 2019
16.8.4. Product Offerings
16.8.5. Recent Initiatives (2017-2019)
16.9. Daiichi Sankyo Company, Limited
16.9.1. Company Snapshot
16.9.2. Company Overview
16.9.3. Financial Performance (2015-2019)
16.9.3.1. Net Revenue
16.9.3.2. Gross Profit
16.9.3.3. Geographical Revenue, 2019
16.9.4. Product Offerings
16.9.5. Recent Initiatives (2017-2019)
16.10. Takeda Pharmaceutical Company Limited
16.10.1. Company Snapshot
16.10.2. Company Overview
16.10.3. Financial Performance (2015-2019)
16.10.3.1. Net Revenue
16.10.3.2. Gross Profit
16.10.3.3. Geographical Revenue, 2019
16.10.4. Product Offerings
16.10.5. Recent Initiatives (2017-2019)
16.11. Johnson & Johnson Services, Inc.
16.11.1. Company Snapshot
16.11.2. Company Overview
16.11.3. Financial Performance (2015-2019)
16.11.3.1. Net Revenue
16.11.3.2. Gross Profit
16.11.3.3. Geographical Revenue, 2019
16.11.4. Product Offerings
16.11.5. Recent Initiatives (2017-2019)
16.12. Lupin
16.12.1. Company Snapshot
16.12.2. Company Overview
16.12.3. Financial Performance (2015-2019)
16.12.3.1. Net Revenue
16.12.3.2. Gross Profit
16.12.3.3. Geographical Revenue, 2019
16.12.4. Product Offerings
16.12.5. Recent Initiatives (2017-2019)
16.13. Merck & Co., Inc.
16.13.1. Company Snapshot
16.13.2. Company Overview
16.13.3. Financial Performance (2015-2019)
16.13.3.1. Net Revenue
16.13.3.2. Gross Profit
16.13.3.3. Geographical Revenue, 2019
16.13.4. Product Offerings
16.13.5. Recent Initiatives (2017-2019)
16.14. Sun Pharmaceutical Industries Ltd.
16.14.1. Company Snapshot
16.14.2. Company Overview
16.14.3. Financial Performance (2015-2019)
16.14.3.1. Net Revenue
16.14.3.2. Gross Profit
16.14.3.3. Geographical Revenue, 2019
16.14.4. Product Offerings
16.14.5. Recent Initiatives (2017-2019)
16.15. AstraZeneca plc
16.15.1. Company Snapshot
16.15.2. Company Overview
16.15.3. Financial Performance (2015-2019)
16.15.3.1. Net Revenue
16.15.3.2. Gross Profit
16.15.3.3. Geographical Revenue, 2019
16.15.4. Product Offerings
16.15.5. Recent Initiatives (2017-2019)
16.16. Other Notable Players
17. Conclusion
18. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
LIST OF TABLES
Table 1. Antihypertensive Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 2. Antihypertensive Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 3. Antihypertensive Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 4. Antihypertensive Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 5. Antihypertensive Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 6. Antihypertensive Drugs Market Drivers & Restraints 2021
Table 7. Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 8. Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 9. Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 10. Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 11. Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 12. Diuretics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 13. Diuretics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 14. Diuretics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 15. Diuretics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 16. Diuretics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 17. Angiotensin Converting Enzyme Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 18. Angiotensin Converting Enzyme Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 19. Angiotensin Converting Enzyme Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 20. Angiotensin Converting Enzyme Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 21. Angiotensin Converting Enzyme Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 22. Angiotensin Receptor Blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 23. Angiotensin Receptor Blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 24. Angiotensin Receptor Blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 25. Angiotensin Receptor Blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 26. Angiotensin Receptor Blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 27. Beta-blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 28. Beta-blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 29. Beta-blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 30. Beta-blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 31. Beta-blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 32. Vasodilators Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 33. Vasodilators Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 34. Vasodilators Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 35. Vasodilators Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 36. Vasodilators Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 37. Calcium Channel Blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 38. Calcium Channel Blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 39. Calcium Channel Blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 40. Calcium Channel Blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 41. Calcium Channel Blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 42. Renin Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 43. Renin Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 44. Renin Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 45. Renin Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 46. Renin Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 47. Alpha-blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 48. Alpha-blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 49. Alpha-blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 50. Alpha-blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 51. Alpha-blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 52. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 53. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 54. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 55. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 56. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 57. Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 58. Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 59. Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 60. Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 61. Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 62. Primary Hypertension Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 63. Primary Hypertension Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 64. Primary Hypertension Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 65. Primary Hypertension Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 66. Primary Hypertension Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 67. Secondary Hypertension Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 68. Secondary Hypertension Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 69. Secondary Hypertension Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 70. Secondary Hypertension Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 71. Secondary Hypertension Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 72. Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 73. Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 74. Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 75. Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 76. Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 77. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 78. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 79. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 80. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 81. Generic Drugs h Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 82. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 83. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 84. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 85. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 86. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 87. Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 88. Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 89. Antihypertensive Drugs Market Forecast By Medication Type Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 90. Antihypertensive Drugs Market Forecast By Medication Type Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 91. Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 92. Monotherapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 93. Monotherapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 94. Monotherapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 95. Monotherapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 96. Monotherapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 97. Combination Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 98. Combination Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 99. Combination Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 100. Combination Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 101. Combination Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 102. Fixed Dose Combinations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 103. Fixed Dose Combinations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 104. Fixed Dose Combinations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 105. Fixed Dose Combinations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 106. Fixed Dose Combinations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 107. Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 108. Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 109. Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 110. Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 111. Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 112. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 113. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 114. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 115. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 116. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 117. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 118. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 119. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 120. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 121. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 122. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 123. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 124. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 125. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 126. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 127. Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 128. Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 129. Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 130. Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 131. Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 132. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 133. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 134. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 135. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 136. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 137. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 138. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 139. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 140. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 141. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 142. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 143. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 144. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 145. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 146. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 147. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 148. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 149. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 150. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 151. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 152. Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 153. Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 154. Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 155. Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 156. Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 157. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 158. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 159. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 160. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 161. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 162. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 163. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 164. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 165. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 166. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 167. Ecommerce Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 168. Ecommerce Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 169. Ecommerce Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 170. Ecommerce Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 171. Ecommerce Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 172. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 173. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 174. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 175. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 176. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 177. North America Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 178. North America Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 179. North America Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 180. North America Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 181. North America Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 182. North America Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 183. North America Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 184. North America Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 185. North America Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 186. North America Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 187. North America Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 188. North America Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 189. North America Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 190. North America Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 191. North America Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 192. North America Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 193. North America Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 194. North America Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 195. North America Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 196. North America Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 197. North America Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 198. North America Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 199. North America Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 200. North America Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 201. North America Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 202. North America Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 203. North America Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 204. North America Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 205. North America Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 206. North America Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 207. North America Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 208. North America Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 209. North America Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 210. North America Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 211. North America Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 212. North America Antihypertensive Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 213. North America Antihypertensive Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 214. North America Antihypertensive Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 215. North America Antihypertensive Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 216. North America Antihypertensive Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 217. US Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 218. US Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 219. US Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 220. US Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 221. US Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 222. Canada Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 223. Canada Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 224. Canada Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 225. Canada Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 226. Canada Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 227. Europe Antihypertensive Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID) Table 82.
Table 228. Europe Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 229. Europe Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 230. Europe Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 231. Europe Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 232. Europe Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 233. Europe Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 234. Europe Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 235. Europe Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 236. Europe Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 237. Europe Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 238. Europe Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 239. Europe Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 240. Europe Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 241. Europe Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 242. Europe Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 243. Europe Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 244. Europe Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 245. Europe Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 246. Europe Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 247. Europe Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 248. Europe Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 249. Europe Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 250. Europe Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 251. Europe Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 252. Europe Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 253. Europe Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 254. Europe Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 255. Europe Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 256. Europe Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 257. Europe Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 258. Europe Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 259. Europe Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 260. Europe Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 261. Europe Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 262. Europe Antihypertensive Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 263. Europe Antihypertensive Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 264. Europe Antihypertensive Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 265. Europe Antihypertensive Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 266. UK Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 267. UK Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 268. UK Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 269. UK Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 270. UK Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 271. Germany Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 272. Germany Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 273. Germany Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 274. Germany Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 275. Germany Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 276. France Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 277. France Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 278. France Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 279. France Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 280. France Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 281. Rest of Europe Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 282. Rest of Europe Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 283. Rest of Europe Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 284. Rest of Europe Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 285. Rest of Europe Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 286. Asia Pacific Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 287. Asia Pacific Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 288. Asia Pacific Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 289. Asia Pacific Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 290. Asia Pacific Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 291. Asia Pacific Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 292. Asia Pacific Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 293. Asia Pacific Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 294. Asia Pacific Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 295. Asia Pacific Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 296. Asia Pacific Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 297. Asia Pacific Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 298. Asia Pacific Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 299. Asia Pacific Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 300. Asia Pacific Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 301. Asia Pacific Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 302. Asia Pacific Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 303. Asia Pacific Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 304. Asia Pacific Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 305. Asia Pacific Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 306. Asia Pacific Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 307. Asia Pacific Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 308. Asia Pacific Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 309. Asia Pacific Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 310. Asia Pacific Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 311. Asia Pacific Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 312. Asia Pacific Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 313. Asia Pacific Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 314. Asia Pacific Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 315. Asia Pacific Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 316. Asia Pacific Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 317. Asia Pacific Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 318. Asia Pacific Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 319. Asia Pacific Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 320. Asia Pacific Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 321. Asia Pacific Antihypertensive Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 322. Asia Pacific Antihypertensive Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 323. Asia Pacific Antihypertensive Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 324. Asia Pacific Antihypertensive Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 325. Asia Pacific Antihypertensive Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 326. China Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 327. China Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 328. China Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 329. China Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 330. China Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 331. India Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 332. India Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 333. India Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 334. India Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 335. India Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 336. Japan Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 337. Japan Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 338. Japan Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 339. Japan Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 340. Japan Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 341. RoAPAC Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 342. RoAPAC Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 343. RoAPAC Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 344. RoAPAC Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 345. RoAPAC Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 346. Middle East Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 347. Middle East Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 348. Middle East Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 349. Middle East Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 350. Middle East Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 351. Middle East Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 352. Middle East Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 353. Middle East Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 354. Middle East Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 355. Middle East Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 356. Middle East Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 357. Middle East Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 358. Middle East Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 359. Middle East Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 360. Middle East Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 361. Middle East Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 362. Middle East Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 363. Middle East Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 364. Middle East Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 365. Middle East Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 366. Middle East Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 367. Middle East Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 368. Middle East Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 369. Middle East Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 370. Middle East Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 371. Middle East Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 372. Middle East Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 373. Middle East Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 374. Middle East Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 375. Middle East Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 376. Middle East Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 377. Middle East Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 378. Middle East Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 379. Middle East Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 380. Middle East Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 381. Latin America Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 382. Latin America Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 383. Latin America Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 384. Latin America Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 385. Latin America Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 386. Latin America Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 387. Latin America Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 388. Latin America Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 389. Latin America Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 390. Latin America Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 391. Latin America Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 392. Latin America Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 393. Latin America Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 394. Latin America Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 395. Latin America Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 396. Latin America Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 397. Latin America Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 398. Latin America Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 399. Latin America Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 400. Latin America Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 401. Latin America Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 402. Latin America Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 403. Latin America Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 404. Latin America Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 405. Latin America Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 406. Latin America Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 407. Latin America Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 408. Latin America Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 409. Latin America Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 410. Latin America Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 411. Latin America Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 412. Latin America Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 413. Latin America Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 414. Latin America Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 415. Latin America Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 416. Africa Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 417. Africa Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 418. Africa Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 419. Africa Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 420. Africa Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 421. Africa Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 422. Africa Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 423. Africa Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 424. Africa Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 425. Africa Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 426. Africa Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 427. Africa Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 428. Africa Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 429. Africa Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 430. Africa Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 431. Africa Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 432. Africa Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 433. Africa Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 434. Africa Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 435. Africa Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 436. Africa Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 437. Africa Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 438. Africa Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 439. Africa Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 440. Africa Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 441. Africa Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 442. Africa Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 443. Africa Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 444. Africa Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 445. Africa Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 446. Africa Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 447. Africa Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 448. Africa Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 449. Africa Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 450. Africa Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 451. Leading 15 Antihypertensive Drugs Companies (Ranking, Company, Latest Total Company Sales US$M*, HQ)
Table 452. Pfizer Inc.Profile 2019 (CEO, HQ, Founded, Website)
Table 453. Pfizer Inc. Antihypertensive Drugs Product Offering (Segment, Product Offerings)
Table 454. Sanofi S.A Profile 2019 (CEO, HQ, Founded, Website)
Table 455. Sanofi S.A Antihypertensive Drugs Product Offering (Segment, Product Offerings)
Table 456. Novartis AG Profile 2019 (CEO, HQ, Founded, Website)
Table 457. Novartis AG.Antihypertensive Drugs Product Offering (Segment, Product Offerings)
Table 458. Boehringer Ingelheim GmbH Profile 2019 (CEO, HQ, Founded, Website)
Table 459. Boehringer Ingelheim GmbH Antihypertensive Drugs Product Offering (Segment, Product Offerings)
Table 460. Actelion Ltd. Profile 2019 (CEO, HQ, Founded, Website)
Table 461. Actelion Ltd. Antihypertensive Drugs Product Offering (Segment, Product Offerings)
Table 462. F. Hoffmann-La Roche Ltd. Profile 2019 (CEO, HQ, Founded, Website)
Table 463. F. Hoffmann-La Roche Ltd. Antihypertensive Drugs Product Offering (Segment, Product Offerings)
Table 464. Bayer AG Profile 2019 (CEO, HQ, Founded, Website)
Table 465. Bayer AG Antihypertensive Drugs Product Offering (Segment, Product Offerings)
Table 466. Glenmark Pharmaceutical Inc. Profile 2019 (CEO, HQ, Founded, Website)
Table 467. Glenmark Pharmaceutical Inc. Antihypertensive Drugs Product Offering (Segment, Product Offerings)
Table 468. Daiichi Sankyo Company, Limited Profile 2019 (CEO, HQ, Founded, Website)
Table 469. Daiichi Sankyo Company, Limited Antihypertensive Drugs Product Offering (Segment, Product Offerings)
Table 470. Takeda Pharmaceutical Company Limited Corporation Profile 2019 (CEO, HQ, Founded, Website)
Table 471. Takeda Pharmaceutical Company Limited Antihypertensive Drugs Product Offering (Segment, Product Offerings)
Table 472. AstraZeneca plc Corporation Profile 2019 (CEO, HQ, Founded, Website)
Table 473. AstraZeneca plc Antihypertensive Drugs Product Offering (Segment, Product Offerings)
Table 474. Johnson & Johnson Services, Inc.Corporation Profile 2019 (CEO, HQ, Founded, Website)
Table 475. Johnson & Johnson Services, Inc.Antihypertensive Drugs Product Offering (Segment, Product Offerings)
Table 476. Lupin Corporation Profile 2019 (CEO, HQ, Founded, Website)
Table 477. Lupin Antihypertensive Drugs Product Offering (Segment, Product Offerings)
Table 478. Merck & Co., Inc. Corporation Profile 2019 (CEO, HQ, Founded, Website)
Table 479. Merck & Co., Inc. .Antihypertensive Drugs Product Offering (Segment, Product Offerings)
Table 480. Sun Pharmaceutical Industries Ltd. Corporation Profile 2019 (CEO, HQ, Founded, Website)
Table 481. Sun Pharmaceutical Industries Ltd..Antihypertensive Drugs Product Offering (Segment, Product Offerings)
Table 482. Other Companies Involved in the Antihypertensive Drugs Market 2021 (Company, Location)
LIST OF FIGURES
Figure 1. Antihypertensive Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 2. Antihypertensive Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 3. Antihypertensive Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 4. Antihypertensive Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 5. Antihypertensive Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 6. Antihypertensive Drugs Market Drivers & Restraints 2021
Figure 7. Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 8. Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 9. Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 10. Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 11. Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 12. Diuretics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 13. Diuretics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 14. Diuretics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 15. Diuretics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 16. Diuretics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 17. Angiotensin Converting Enzyme Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 18. Angiotensin Converting Enzyme Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 19. Angiotensin Converting Enzyme Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 20. Angiotensin Converting Enzyme Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 21. Angiotensin Converting Enzyme Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 22. Angiotensin Receptor Blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 23. Angiotensin Receptor Blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 24. Angiotensin Receptor Blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 25. Angiotensin Receptor Blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 26. Angiotensin Receptor Blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 27. Beta-blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 28. Beta-blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 29. Beta-blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 30. Beta-blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 31. Beta-blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 32. Vasodilators Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 33. Vasodilators Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 34. Vasodilators Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 35. Vasodilators Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 36. Vasodilators Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 37. Calcium Channel Blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 38. Calcium Channel Blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 39. Calcium Channel Blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 40. Calcium Channel Blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 41. Calcium Channel Blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 42. Renin Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 43. Renin Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 44. Renin Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 45. Renin Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 46. Renin Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 47. Alpha-blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 48. Alpha-blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 49. Alpha-blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 50. Alpha-blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 51. Alpha-blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 52. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 53. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 54. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 55. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 56. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 57. Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 58. Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 59. Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 60. Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 61. Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 62. Primary Hypertension Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 63. Primary Hypertension Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 64. Primary Hypertension Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 65. Primary Hypertension Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 66. Primary Hypertension Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 67. Secondary Hypertension Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 68. Secondary Hypertension Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 69. Secondary Hypertension Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 70. Secondary Hypertension Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 71. Secondary Hypertension Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 72. Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 73. Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 74. Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 75. Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 76. Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 77. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 78. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 79. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 80. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 81. Generic Drugs h Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 82. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 83. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 84. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 85. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 86. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 87. Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 88. Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 89. Antihypertensive Drugs Market Forecast By Medication Type Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 90. Antihypertensive Drugs Market Forecast By Medication Type Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 91. Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 92. Monotherapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 93. Monotherapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 94. Monotherapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 95. Monotherapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 96. Monotherapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 97. Combination Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 98. Combination Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 99. Combination Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 100. Combination Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 101. Combination Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 102. Fixed Dose Combinations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 103. Fixed Dose Combinations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 104. Fixed Dose Combinations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 105. Fixed Dose Combinations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 106. Fixed Dose Combinations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 107. Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 108. Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 109. Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 110. Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 111. Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 112. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 113. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 114. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 115. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 116. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 117. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 118. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 119. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 120. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 121. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 122. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 123. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 124. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 125. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 126. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 127. Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 128. Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 129. Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 130. Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 131. Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 132. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 133. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 134. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 135. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 136. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 137. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 138. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 139. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 140. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 141. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 142. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 143. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 144. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 145. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 146. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 147. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 148. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 149. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 150. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 151. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 152. Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 153. Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 154. Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 155. Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 156. Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 157. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 158. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 159. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 160. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 161. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 162. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 163. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 164. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 165. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 166. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 167. Ecommerce Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 168. Ecommerce Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 169. Ecommerce Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 170. Ecommerce Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 171. Ecommerce Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 172. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 173. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 174. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 175. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 176. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 177. North America Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 178. North America Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 179. North America Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 180. North America Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 181. North America Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 182. North America Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 183. North America Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 184. North America Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 185. North America Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 186. North America Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 187. North America Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 188. North America Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 189. North America Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 190. North America Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 191. North America Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 192. North America Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 193. North America Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 194. North America Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 195. North America Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 196. North America Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 197. North America Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 198. North America Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 199. North America Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 200. North America Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 201. North America Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 202. North America Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 203. North America Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 204. North America Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 205. North America Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 206. North America Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 207. North America Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 208. North America Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 209. North America Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 210. North America Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 211. North America Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 212. North America Antihypertensive Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 213. North America Antihypertensive Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 214. North America Antihypertensive Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 215. North America Antihypertensive Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 216. North America Antihypertensive Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 217. US Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 218. US Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 219. US Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 220. US Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 221. US Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 222. Canada Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 223. Canada Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 224. Canada Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 225. Canada Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 226. Canada Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 227. Europe Antihypertensive Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID) Table 82.
Figure 228. Europe Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 229. Europe Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 230. Europe Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 231. Europe Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 232. Europe Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 233. Europe Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 234. Europe Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 235. Europe Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 236. Europe Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 237. Europe Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 238. Europe Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 239. Europe Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 240. Europe Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 241. Europe Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 242. Europe Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 243. Europe Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 244. Europe Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 245. Europe Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 246. Europe Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 247. Europe Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 248. Europe Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 249. Europe Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 250. Europe Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 251. Europe Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 252. Europe Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 253. Europe Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 254. Europe Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 255. Europe Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 256. Europe Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 257. Europe Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 258. Europe Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 259. Europe Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 260. Europe Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 261. Europe Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 262. Europe Antihypertensive Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 263. Europe Antihypertensive Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 264. Europe Antihypertensive Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 265. Europe Antihypertensive Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 266. UK Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 267. UK Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 268. UK Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 269. UK Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 270. UK Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 271. Germany Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 272. Germany Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 273. Germany Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 274. Germany Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 275. Germany Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 276. France Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 277. France Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 278. France Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 279. France Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 280. France Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 281. Rest of Europe Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 282. Rest of Europe Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 283. Rest of Europe Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 284. Rest of Europe Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 285. Rest of Europe Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 286. Asia Pacific Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 287. Asia Pacific Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 288. Asia Pacific Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 289. Asia Pacific Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 290. Asia Pacific Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 291. Asia Pacific Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 292. Asia Pacific Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 293. Asia Pacific Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 294. Asia Pacific Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 295. Asia Pacific Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 296. Asia Pacific Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 297. Asia Pacific Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 298. Asia Pacific Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 299. Asia Pacific Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 300. Asia Pacific Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 301. Asia Pacific Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 302. Asia Pacific Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 303. Asia Pacific Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 304. Asia Pacific Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 305. Asia Pacific Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 306. Asia Pacific Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 307. Asia Pacific Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 308. Asia Pacific Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 309. Asia Pacific Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 310. Asia Pacific Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 311. Asia Pacific Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 312. Asia Pacific Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 313. Asia Pacific Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 314. Asia Pacific Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 315. Asia Pacific Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 316. Asia Pacific Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 317. Asia Pacific Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 318. Asia Pacific Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 319. Asia Pacific Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 320. Asia Pacific Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 321. Asia Pacific Antihypertensive Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 322. Asia Pacific Antihypertensive Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 323. Asia Pacific Antihypertensive Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 324. Asia Pacific Antihypertensive Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 325. Asia Pacific Antihypertensive Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 326. China Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 327. China Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 328. China Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 329. China Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 330. China Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 331. India Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 332. India Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 333. India Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 334. India Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 335. India Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 336. Japan Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 337. Japan Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 338. Japan Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 339. Japan Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 340. Japan Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 341. RoAPAC Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 342. RoAPAC Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 343. RoAPAC Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 344. RoAPAC Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 345. RoAPAC Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 346. Middle East Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 347. Middle East Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 348. Middle East Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 349. Middle East Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 350. Middle East Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 351. Middle East Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 352. Middle East Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 353. Middle East Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 354. Middle East Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 355. Middle East Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 356. Middle East Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 357. Middle East Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 358. Middle East Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 359. Middle East Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 360. Middle East Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 361. Middle East Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 362. Middle East Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 363. Middle East Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 364. Middle East Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 365. Middle East Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 366. Middle East Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 367. Middle East Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 368. Middle East Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 369. Middle East Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 370. Middle East Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 371. Middle East Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 372. Middle East Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 373. Middle East Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 374. Middle East Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 375. Middle East Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 376. Middle East Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 377. Middle East Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 378. Middle East Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 379. Middle East Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 380. Middle East Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 381. Latin America Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 382. Latin America Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 383. Latin America Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 384. Latin America Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 385. Latin America Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 386. Latin America Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 387. Latin America Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 388. Latin America Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 389. Latin America Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 390. Latin America Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 391. Latin America Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 392. Latin America Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 393. Latin America Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 394. Latin America Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 395. Latin America Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 396. Latin America Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 397. Latin America Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 398. Latin America Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 399. Latin America Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 400. Latin America Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 401. Latin America Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 402. Latin America Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 403. Latin America Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 404. Latin America Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 405. Latin America Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 406. Latin America Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 407. Latin America Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 408. Latin America Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 409. Latin America Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 410. Latin America Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 411. Latin America Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 412. Latin America Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 413. Latin America Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 414. Latin America Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 415. Latin America Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 416. Africa Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 417. Africa Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 418. Africa Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 419. Africa Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 420. Africa Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 421. Africa Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 422. Africa Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 423. Africa Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 424. Africa Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 425. Africa Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 426. Africa Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 427. Africa Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 428. Africa Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 429. Africa Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 430. Africa Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 431. Africa Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 432. Africa Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 433. Africa Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 434. Africa Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 435. Africa Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 436. Africa Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 437. Africa Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 438. Africa Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 439. Africa Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 440. Africa Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 441. Africa Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 442. Africa Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 443. Africa Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 444. Africa Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 445. Africa Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 446. Africa Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 447. Africa Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 448. Africa Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 449. Africa Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 450. Africa Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 451. Leading 15 Antihypertensive Drugs Companies (Ranking, Company, Latest Total Company Sales US$M*, HQ)
Figure 452. Pfizer Inc.Profile 2019 (CEO, HQ, Founded, Website)
Figure 453. Pfizer Inc. Antihypertensive Drugs Product Offering (Segment, Product Offerings)
Figure 454. Sanofi S.A Profile 2019 (CEO, HQ, Founded, Website)
Figure 455. Sanofi S.A Antihypertensive Drugs Product Offering (Segment, Product Offerings)
Figure 456. Novartis AG Profile 2019 (CEO, HQ, Founded, Website)
Figure 457. Novartis AG.Antihypertensive Drugs Product Offering (Segment, Product Offerings)
Figure 458. Boehringer Ingelheim GmbH Profile 2019 (CEO, HQ, Founded, Website)
Figure 459. Boehringer Ingelheim GmbH Antihypertensive Drugs Product Offering (Segment, Product Offerings)
Figure 460. Actelion Ltd. Profile 2019 (CEO, HQ, Founded, Website)
Figure 461. Actelion Ltd. Antihypertensive Drugs Product Offering (Segment, Product Offerings)
Figure 462. F. Hoffmann-La Roche Ltd. Profile 2019 (CEO, HQ, Founded, Website)
Figure 463. F. Hoffmann-La Roche Ltd. Antihypertensive Drugs Product Offering (Segment, Product Offerings)
Figure 464. Bayer AG Profile 2019 (CEO, HQ, Founded, Website)
Figure 465. Bayer AG Antihypertensive Drugs Product Offering (Segment, Product Offerings)
Figure 466. Glenmark Pharmaceutical Inc. Profile 2019 (CEO, HQ, Founded, Website)
Figure 467. Glenmark Pharmaceutical Inc. Antihypertensive Drugs Product Offering (Segment, Product Offerings)
Figure 468. Daiichi Sankyo Company, Limited Profile 2019 (CEO, HQ, Founded, Website)
Figure 469. Daiichi Sankyo Company, Limited Antihypertensive Drugs Product Offering (Segment, Product Offerings)
Figure 470. Takeda Pharmaceutical Company Limited Corporation Profile 2019 (CEO, HQ, Founded, Website)
Figure 471. Takeda Pharmaceutical Company Limited Antihypertensive Drugs Product Offering (Segment, Product Offerings)
Figure 472. AstraZeneca plc Corporation Profile 2019 (CEO, HQ, Founded, Website)
Figure 473. AstraZeneca plc Antihypertensive Drugs Product Offering (Segment, Product Offerings)
Figure 474. Johnson & Johnson Services, Inc.Corporation Profile 2019 (CEO, HQ, Founded, Website)
Figure 475. Johnson & Johnson Services, Inc.Antihypertensive Drugs Product Offering (Segment, Product Offerings)
Figure 476. Lupin Corporation Profile 2019 (CEO, HQ, Founded, Website)
Figure 477. Lupin Antihypertensive Drugs Product Offering (Segment, Product Offerings)
Figure 478. Merck & Co., Inc. Corporation Profile 2019 (CEO, HQ, Founded, Website)
Figure 479. Merck & Co., Inc. .Antihypertensive Drugs Product Offering (Segment, Product Offerings)
Figure 480. Sun Pharmaceutical Industries Ltd. Corporation Profile 2019 (CEO, HQ, Founded, Website)
Figure 481. Sun Pharmaceutical Industries Ltd..Antihypertensive Drugs Product Offering (Segment, Product Offerings)
Figure 482. Other Companies Involved in the Antihypertensive Drugs Market 2021 (Company, Location)
Figure 483. Porter’s Five Force Analysis
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered By This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated Visiongain Reports
1.8. About Visiongain
2. Introduction to the Antihypertensive Drugs Market
2.1. Antihypertensive Drugs Market Definition
2.2. Application Submarkets Definitions
2.3. Component Submarkets Definitions
2.4. Condition Submarkets Definitions
3. Antihypertensive Drugs Market Overview
3.1. Global Antihypertensive Drugs Market Size and Forecast By Region
3.2. Global Antihypertensive Drugs Market Share By Region
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Increasing prevalence of hypertensive
3.3.1.2. Increasing strategic initiatives in antihypertensive drugs market
3.3.1.3. Increasing regulatory approvals in antihypertensive drugs market
3.3.1.4. Growing demand for antihypertensive drugs in emerging economies
3.3.2. Market Restraints/Challenges
3.3.2.1. Stringent regulation associated with product development
3.3.2.2. High cost of development
3.3.3. Opportunities
3.3.3.1. Increasing awareness program
3.3.3.2. Increasing therapeutic advancements in antihypertensive drugs
3.3.4. Challenges
3.3.4.1. Changing geopolitical scenario
3.3.4.2. Increasing number of player in the market
3.3.5. SWOT Analysis
3.3.5.1. Strengths
3.3.5.1.1. Strength 1
3.3.5.1.2. Strength 2
3.3.5.1.3. Strength 3
3.3.5.2. Weaknesses
3.3.5.2.1. Weakness 1
3.3.5.2.2. Weakness 2
3.3.5.2.3. Weakness 3
3.3.5.3. Opportunities
3.3.5.3.1. Opportunity 1
3.3.5.3.2. Opportunity 2
3.3.5.3.3. Opportunity 3
3.3.5.4. Threats
3.3.5.4.1. Threat 1
3.3.5.4.2. Threat 2
3.3.5.4.3. Threat 3
3.3.6. Porter’s Five Forces Analysis
3.3.6.1. Competitive Rivalry
3.3.6.2. Supplier Power
3.3.6.3. Buyer Power
3.3.6.4. Threat of Substitution
3.3.6.5. Threat of New Entry
4. Global Antihypertensive Drugs Market Analysis and Forecast 2021-2031, By Drug (Pre COVID and V, U, W and L COVID Recovery Scenarios)
4.1. Market Overview
4.1.1. Diuretics
4.1.1.1. Diuretics market size and forecast, 2021-2031 (USD Million)
4.1.2. Angiotensin Converting Enzyme Inhibitors
4.1.2.1. Angiotensin Converting Enzyme Inhibitors market size and forecast, 2021-2031 (USD Million)
4.1.3. Angiotensin Receptor Blockers
4.1.3.1. Angiotensin Receptor Blockers market size and forecast, 2021-2031 (USD Million)
4.1.4. Beta-blockers
4.1.4.1. Beta-blockers market size and forecast, 2021-2031 (USD Million)
4.1.5. Vasodilators
4.1.5.1. Vasodilators market size and forecast, 2021-2031 (USD Million)
4.1.6. Calcium Channel Blockers
4.1.6.1. Calcium Channel Blockers market size and forecast, 2021-2031 (USD Million)
4.1.7. Renin Inhibitors
4.1.7.1. Renin Inhibitors market size and forecast, 2021-2031 (USD Million)
4.1.8. Alpha-blockers
4.1.8.1. Alpha-blockers market size and forecast, 2021-2031 (USD Million)
4.1.9. Others
4.1.9.1. Others market size and forecast, 2021-2031 (USD Million)
5. Global Antihypertensive Drugs Market Analysis and Forecast, 2021-2031 By Condition (Pre COVID and V, U, W and L COVID Recovery Scenarios)
5.1. Market Overview
5.1.1. Primary Hypertension
5.1.1.1. Primary Hypertension market size and forecast, 2021-2031 (USD Million)
5.1.2. Secondary Hypertension
5.1.2.1. Secondary Hypertension market size and forecast, 2021-2031 (USD Million)
6. Global Antihypertensive Drugs Market Analysis and Forecast, 2021-2031 By Medication Type (Pre COVID and V, U, W and L COVID Recovery Scenarios)
6.1. Market Overview
6.1.1. Monotherapy
6.1.1.1. Monotherapy market size and forecast, 2021-2031 (USD Million)
6.1.2. Combination Therapy
6.1.2.1. Combination Therapy market size and forecast, 2021-2031 (USD Million)
6.1.3. Fixed Dose Combinations
6.1.3.1. Fixed Dose Combinations market size and forecast, 2021-2031 (USD Million)
7. Global Antihypertensive Drugs Market Analysis and Forecast, 2021-2031 By Drug Type (Pre COVID and V, U, W and L COVID Recovery Scenarios)
7.1. Market Overview
7.1.1. Generic Drugs
7.1.1.1. Generic Drugs market size and forecast, 2021-2031 (USD Million)
7.1.2. Branded Drugs
7.1.2.1. Branded Drugs market size and forecast, 2021-2031 (USD Million)
8. Global Antihypertensive Drugs Market Analysis and Forecast, 2021-2031 By Patient Demographics (Pre COVID and V, U, W and L COVID Recovery Scenarios)
8.1. Market Overview
8.1.1. Geriatric Patient
8.1.1.1. Geriatric Patient market size and forecast, 2021-2031 (USD Million)
8.1.2. Adult Patient
8.1.2.1. Adult Patient market size and forecast, 2021-2031 (USD Million)
8.1.3. Pediatric
8.1.3.1. Pediatric market size and forecast, 2021-2031 (USD Million)
9. Global Antihypertensive Drugs Market Analysis and Forecast, 2021-2031 By End-User (Pre COVID and V, U, W and L COVID Recovery Scenarios)
9.1. Market Overview
9.1.1. Hospitals
9.1.1.1. Hospitals market size and forecast, 2021-2031 (USD Million)
9.1.2. Homecare
9.1.2.1. Homecare market size and forecast, 2021-2031 (USD Million)
9.1.3. Specialty Clinics
9.1.3.1. Specialty Clinics market size and forecast, 2021-2031 (USD Million)
9.1.4. Others
9.1.4.1. Others market size and forecast, 2021-2031 (USD Million)
10. Global Antihypertensive Drugs Market Analysis and Forecast, 2021-2031 By Distribution Channel (Pre COVID and V, U, W and L COVID Recovery Scenarios)
10.1. Market Overview
10.1.1. Hospitals Pharmacy
10.1.1.1. Hospitals Pharmacy market size and forecast, 2021-2031 (USD Million)
10.1.2. Retail Pharmacy
10.1.2.1. Retail Pharmacy market size and forecast, 2021-2031 (USD Million)
10.1.3. Ecommerce
10.1.3.1. Ecommerce market size and forecast, 2021-2031 (USD Million)
10.1.4. Others
10.1.4.1. Others market size and forecast, 2021-2031 (USD Million)
11. North America Antihypertensive Drugs Market Analysis and Forecast, 2021-2031 Pre COVID and V, U, W and L COVID Recovery Scenarios)
11.1. Market Overview
11.2. North America Antihypertensive Drugs Market Size and Forecast By Drug
11.2.1.1. XX Driving/Opportunity Factor
11.2.1.2. XX Driving/Opportunity Factor
11.3. North America Antihypertensive Drugs Market Size and Forecast By Condition
11.3.1.1. XX Driving/Opportunity Factor
11.3.1.2. XX Driving/Opportunity Factor
11.4. North America Antihypertensive Drugs Market Size and Forecast By Medication Type
11.4.1.1. XX Driving/Opportunity Factor
11.4.1.2. XX Driving/Opportunity Factor
11.5. North America Antihypertensive Drugs Market Size and Forecast By Patient Demographics
11.5.1.1. XX Driving/Opportunity Factor
11.5.1.2. XX Driving/Opportunity Factor
11.6. North America Antihypertensive Drugs Market Size and Forecast By Drug Type
11.6.1.1. XX Driving/Opportunity Factor
11.6.1.2. XX Driving/Opportunity Factor
11.7. North America Antihypertensive Drugs Market Size and Forecast By End-User
11.7.1.1. XX Driving/Opportunity Factor
11.7.1.2. XX Driving/Opportunity Factor
11.8. North America Antihypertensive Drugs Market Size and Forecast By Distribution Channel
11.8.1.1. XX Driving/Opportunity Factor
11.8.1.2. XX Driving/Opportunity Factor
11.9. U.S. Antihypertensive Drugs Market
11.9.1.1. XX Driving/Opportunity Factor
11.9.1.2. XX Driving/Opportunity Factor
11.10. Canada Antihypertensive Drugs Market
11.10.1.1. XX Driving/Opportunity Factor
11.10.1.2. XX Driving/Opportunity Factor
12. Europe Antihypertensive Drugs Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
12.1. Market Overview
12.2. Europe Antihypertensive Drugs Market Size and Forecast By Drug
12.2.1.1. XX Driving/Opportunity Factor
12.2.1.2. XX Driving/Opportunity Factor
12.3. Europe Antihypertensive Drugs Market Size and Forecast By Condition
12.3.1.1. XX Driving/Opportunity Factor
12.3.1.2. XX Driving/Opportunity Factor
12.4. Europe Antihypertensive Drugs Market Size and Forecast By Medication Type
12.4.1.1. XX Driving/Opportunity Factor
12.4.1.2. XX Driving/Opportunity Factor
12.5. Europe Antihypertensive Drugs Market Size and Forecast By Patient Demographics
12.5.1.1. XX Driving/Opportunity Factor
12.5.1.2. XX Driving/Opportunity Factor
12.6. Europe Antihypertensive Drugs Market Size and Forecast By Drug Type
12.6.1.1. XX Driving/Opportunity Factor
12.6.1.2. XX Driving/Opportunity Factor
12.7. Europe Antihypertensive Drugs Market Size and Forecast By End-User
12.7.1.1. XX Driving/Opportunity Factor
12.7.1.2. XX Driving/Opportunity Factor
12.8. Europe Antihypertensive Drugs Market Size and Forecast By Distribution Channel
12.8.1.1. XX Driving/Opportunity Factor
12.8.1.2. XX Driving/Opportunity Factor
12.9. UK Antihypertensive Drugs Market
12.9.1.1. XX Driving/Opportunity Factor
12.9.1.2. XX Driving/Opportunity Factor
12.10. Germany Antihypertensive Drugs Market
12.10.1.1. XX Driving/Opportunity Factor
12.10.1.2. XX Driving/Opportunity Factor
12.11. France Antihypertensive Drugs Market
12.11.1.1. XX Driving/Opportunity Factor
12.11.1.2. XX Driving/Opportunity Factor
12.12. Rest of Europe Antihypertensive Drugs Market
12.12.1.1. XX Driving/Opportunity Factor
12.12.1.2. XX Driving/Opportunity Factor
13. Asia Pacific Antihypertensive Drugs Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
13.1. Market Overview
13.2. Asia-Pacific Antihypertensive Drugs Market Size and Forecast By Drug
13.2.1.1. XX Driving/Opportunity Factor
13.2.1.2. XX Driving/Opportunity Factor
13.3. Asia-Pacific Antihypertensive Drugs Market Size and Forecast By Condition
13.3.1.1. XX Driving/Opportunity Factor
13.3.1.2. XX Driving/Opportunity Factor
13.4. Asia-Pacific Antihypertensive Drugs Market Size and Forecast By Medication Type
13.4.1.1. XX Driving/Opportunity Factor
13.4.1.2. XX Driving/Opportunity Factor
13.5. Asia-Pacific Antihypertensive Drugs Market Size and Forecast By Patient Demographics
13.5.1.1. XX Driving/Opportunity Factor
13.5.1.2. XX Driving/Opportunity Factor
13.6. Asia-Pacific Antihypertensive Drugs Market Size and Forecast By Drug Type
13.6.1.1. XX Driving/Opportunity Factor
13.6.1.2. XX Driving/Opportunity Factor
13.7. Asia-Pacific Antihypertensive Drugs Market Size and Forecast By End-User
13.7.1.1. XX Driving/Opportunity Factor
13.7.1.2. XX Driving/Opportunity Factor
13.8. Asia-Pacific Antihypertensive Drugs Market Size and Forecast By Distribution Channel
13.8.1.1. XX Driving/Opportunity Factor
13.8.1.2. XX Driving/Opportunity Factor
13.9. China Antihypertensive Drugs Market
13.9.1.1. XX Driving/Opportunity Factor
13.9.1.2. XX Driving/Opportunity Factor
13.10. India Antihypertensive Drugs Market
13.10.1.1. XX Driving/Opportunity Factor
13.10.1.2. XX Driving/Opportunity Factor
13.11. Japan Antihypertensive Drugs Market
13.11.1.1. XX Driving/Opportunity Factor
13.11.1.2. XX Driving/Opportunity Factor
13.12. Rest of Asia Pacific Antihypertensive Drugs Market
13.12.1.1. XX Driving/Opportunity Factor
13.12.1.2. XX Driving/Opportunity Factor
14. Latin America Antihypertensive Drugs Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
14.1. Market Overview
14.2. Latin America Antihypertensive Drugs Market Size and Forecast By Drug
14.2.1.1. XX Driving/Opportunity Factor
14.2.1.2. XX Driving/Opportunity Factor
14.3. Latin America Antihypertensive Drugs Market Size and Forecast By Condition
14.3.1.1. XX Driving/Opportunity Factor
14.3.1.2. XX Driving/Opportunity Factor
14.4. Latin America Antihypertensive Drugs Market Size and Forecast By Medication Type
14.4.1.1. XX Driving/Opportunity Factor
14.4.1.2. XX Driving/Opportunity Factor
14.5. Latin America Antihypertensive Drugs Market Size and Forecast By Patient Demographics
14.5.1.1. XX Driving/Opportunity Factor
14.5.1.2. XX Driving/Opportunity Factor
14.6. Latin America Antihypertensive Drugs Market Size and Forecast By Drug Type
14.6.1.1. XX Driving/Opportunity Factor
14.6.1.2. XX Driving/Opportunity Factor
14.7. Latin America Antihypertensive Drugs Market Size and Forecast By End-User
14.7.1.1. XX Driving/Opportunity Factor
14.7.1.2. XX Driving/Opportunity Factor
14.8. Latin America Antihypertensive Drugs Market Size and Forecast By Distribution Channel
14.9. Brazil Antihypertensive Drugs Market
14.9.1.1. XX Driving/Opportunity Factor
14.9.1.2. XX Driving/Opportunity Factor
14.10. Mexico Antihypertensive Drugs Market
14.10.1.1. XX Driving/Opportunity Factor
14.10.1.2. XX Driving/Opportunity Factor
14.11. Rest of Latin America Antihypertensive Drugs Market
14.11.1.1. XX Driving/Opportunity Factor
14.11.1.2. XX Driving/Opportunity Factor
15. MEA Antihypertensive Drugs Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
15.1. Market Overview
15.2. MEA Antihypertensive Drugs Market Size and Forecast By Drug
15.2.1.1. XX Driving/Opportunity Factor
15.2.1.2. XX Driving/Opportunity Factor
15.3. MEA Antihypertensive Drugs Market Size and Forecast By Condition
15.3.1.1. XX Driving/Opportunity Factor
15.3.1.2. XX Driving/Opportunity Factor
15.4. MEA Antihypertensive Drugs Market Size and Forecast By Medication Type
15.4.1.1. XX Driving/Opportunity Factor
15.4.1.2. XX Driving/Opportunity Factor
15.5. MEA Antihypertensive Drugs Market Size and Forecast By Patient Demographics
15.5.1.1. XX Driving/Opportunity Factor
15.5.1.2. XX Driving/Opportunity Factor
15.6. MEA Antihypertensive Drugs Market Size and Forecast By Drug Type
15.6.1.1. XX Driving/Opportunity Factor
15.6.1.2. XX Driving/Opportunity Factor
15.7. MEA Antihypertensive Drugs Market Size and Forecast By End-User
15.7.1.1. XX Driving/Opportunity Factor
15.7.1.2. XX Driving/Opportunity Factor
15.8. MEA Antihypertensive Drugs Market Size and Forecast By Distribution Channel
15.8.1.1. XX Driving/Opportunity Factor
15.8.1.2. XX Driving/Opportunity Factor
15.9. GCC Antihypertensive Drugs Market
15.9.1.1. XX Driving/Opportunity Factor
15.9.1.2. XX Driving/Opportunity Factor
15.10. South Africa Antihypertensive Drugs Market
15.10.1.1. XX Driving/Opportunity Factor
15.10.1.2. XX Driving/Opportunity Factor
15.11. Rest of MEA Antihypertensive Drugs Market
15.11.1.1. XX Driving/Opportunity Factor
15.11.1.2. XX Driving/Opportunity Factor
16. Companies in the Antihypertensive Drugs Market
16.1. Pfizer Inc.
16.1.1. Company Snapshot
16.1.2. Company Overview
16.1.3. Financial Performance (2015-2019)
16.1.3.1. Net Revenue
16.1.3.2. Gross Profit
16.1.3.3. Geographical Revenue, 2019
16.1.4. Product Offerings
16.1.5. Recent Initiatives (2017-2019)
16.2. Sanofi S.A
16.2.1. Company Snapshot
16.2.2. Company Overview
16.2.3. Financial Performance (2015-2019)
16.2.3.1. Net Revenue
16.2.3.2. Gross Profit
16.2.3.3. Geographical Revenue, 2019
16.2.4. Product Offerings
16.2.5. Recent Initiatives (2017-2019)
16.3. Novartis AG
16.3.1. Company Snapshot
16.3.2. Company Overview
16.3.3. Financial Performance (2015-2019)
16.3.3.1. Net Revenue
16.3.3.2. Gross Profit
16.3.3.3. Geographical Revenue, 2019
16.3.4. Product Offerings
16.3.5. Recent Initiatives (2017-2019)
16.4. Boehringer Ingelheim GmbH
16.4.1. Company Snapshot
16.4.2. Company Overview
16.4.3. Financial Performance (2015-2019)
16.4.3.1. Net Revenue
16.4.3.2. Gross Profit
16.4.3.3. Geographical Revenue, 2019
16.4.4. Product Offerings
16.4.5. Recent Initiatives (2017-2019)
16.5. Actelion Ltd.
16.5.1. Company Snapshot
16.5.2. Company Overview
16.5.3. Financial Performance (2015-2019)
16.5.3.1. Net Revenue
16.5.3.2. Gross Profit
16.5.3.3. Geographical Revenue, 2019
16.5.4. Product Offerings
16.5.5. Recent Initiatives (2017-2019)
16.6. F. Hoffmann-La Roche Ltd.
16.6.1. Company Snapshot
16.6.2. Company Overview
16.6.3. Financial Performance (2015-2019)
16.6.3.1. Net Revenue
16.6.3.2. Gross Profit
16.6.3.3. Geographical Revenue, 2019
16.6.4. Product Offerings
16.6.5. Recent Initiatives (2017-2019)
16.7. Bayer AG
16.7.1. Company Snapshot
16.7.2. Company Overview
16.7.3. Financial Performance (2015-2019)
16.7.3.1. Net Revenue
16.7.3.2. Gross Profit
16.7.3.3. Geographical Revenue, 2019
16.7.4. Product Offerings
16.7.5. Recent Initiatives (2017-2019)
16.8. Glenmark Pharmaceutical Inc.
16.8.1. Company Snapshot
16.8.2. Company Overview
16.8.3. Financial Performance (2015-2019)
16.8.3.1. Net Revenue
16.8.3.2. Gross Profit
16.8.3.3. Geographical Revenue, 2019
16.8.4. Product Offerings
16.8.5. Recent Initiatives (2017-2019)
16.9. Daiichi Sankyo Company, Limited
16.9.1. Company Snapshot
16.9.2. Company Overview
16.9.3. Financial Performance (2015-2019)
16.9.3.1. Net Revenue
16.9.3.2. Gross Profit
16.9.3.3. Geographical Revenue, 2019
16.9.4. Product Offerings
16.9.5. Recent Initiatives (2017-2019)
16.10. Takeda Pharmaceutical Company Limited
16.10.1. Company Snapshot
16.10.2. Company Overview
16.10.3. Financial Performance (2015-2019)
16.10.3.1. Net Revenue
16.10.3.2. Gross Profit
16.10.3.3. Geographical Revenue, 2019
16.10.4. Product Offerings
16.10.5. Recent Initiatives (2017-2019)
16.11. Johnson & Johnson Services, Inc.
16.11.1. Company Snapshot
16.11.2. Company Overview
16.11.3. Financial Performance (2015-2019)
16.11.3.1. Net Revenue
16.11.3.2. Gross Profit
16.11.3.3. Geographical Revenue, 2019
16.11.4. Product Offerings
16.11.5. Recent Initiatives (2017-2019)
16.12. Lupin
16.12.1. Company Snapshot
16.12.2. Company Overview
16.12.3. Financial Performance (2015-2019)
16.12.3.1. Net Revenue
16.12.3.2. Gross Profit
16.12.3.3. Geographical Revenue, 2019
16.12.4. Product Offerings
16.12.5. Recent Initiatives (2017-2019)
16.13. Merck & Co., Inc.
16.13.1. Company Snapshot
16.13.2. Company Overview
16.13.3. Financial Performance (2015-2019)
16.13.3.1. Net Revenue
16.13.3.2. Gross Profit
16.13.3.3. Geographical Revenue, 2019
16.13.4. Product Offerings
16.13.5. Recent Initiatives (2017-2019)
16.14. Sun Pharmaceutical Industries Ltd.
16.14.1. Company Snapshot
16.14.2. Company Overview
16.14.3. Financial Performance (2015-2019)
16.14.3.1. Net Revenue
16.14.3.2. Gross Profit
16.14.3.3. Geographical Revenue, 2019
16.14.4. Product Offerings
16.14.5. Recent Initiatives (2017-2019)
16.15. AstraZeneca plc
16.15.1. Company Snapshot
16.15.2. Company Overview
16.15.3. Financial Performance (2015-2019)
16.15.3.1. Net Revenue
16.15.3.2. Gross Profit
16.15.3.3. Geographical Revenue, 2019
16.15.4. Product Offerings
16.15.5. Recent Initiatives (2017-2019)
16.16. Other Notable Players
17. Conclusion
18. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
LIST OF TABLES
Table 1. Antihypertensive Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 2. Antihypertensive Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 3. Antihypertensive Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 4. Antihypertensive Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 5. Antihypertensive Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 6. Antihypertensive Drugs Market Drivers & Restraints 2021
Table 7. Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 8. Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 9. Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 10. Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 11. Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 12. Diuretics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 13. Diuretics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 14. Diuretics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 15. Diuretics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 16. Diuretics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 17. Angiotensin Converting Enzyme Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 18. Angiotensin Converting Enzyme Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 19. Angiotensin Converting Enzyme Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 20. Angiotensin Converting Enzyme Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 21. Angiotensin Converting Enzyme Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 22. Angiotensin Receptor Blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 23. Angiotensin Receptor Blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 24. Angiotensin Receptor Blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 25. Angiotensin Receptor Blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 26. Angiotensin Receptor Blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 27. Beta-blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 28. Beta-blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 29. Beta-blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 30. Beta-blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 31. Beta-blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 32. Vasodilators Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 33. Vasodilators Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 34. Vasodilators Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 35. Vasodilators Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 36. Vasodilators Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 37. Calcium Channel Blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 38. Calcium Channel Blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 39. Calcium Channel Blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 40. Calcium Channel Blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 41. Calcium Channel Blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 42. Renin Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 43. Renin Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 44. Renin Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 45. Renin Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 46. Renin Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 47. Alpha-blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 48. Alpha-blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 49. Alpha-blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 50. Alpha-blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 51. Alpha-blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 52. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 53. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 54. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 55. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 56. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 57. Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 58. Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 59. Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 60. Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 61. Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 62. Primary Hypertension Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 63. Primary Hypertension Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 64. Primary Hypertension Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 65. Primary Hypertension Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 66. Primary Hypertension Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 67. Secondary Hypertension Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 68. Secondary Hypertension Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 69. Secondary Hypertension Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 70. Secondary Hypertension Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 71. Secondary Hypertension Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 72. Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 73. Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 74. Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 75. Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 76. Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 77. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 78. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 79. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 80. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 81. Generic Drugs h Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 82. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 83. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 84. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 85. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 86. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 87. Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 88. Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 89. Antihypertensive Drugs Market Forecast By Medication Type Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 90. Antihypertensive Drugs Market Forecast By Medication Type Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 91. Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 92. Monotherapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 93. Monotherapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 94. Monotherapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 95. Monotherapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 96. Monotherapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 97. Combination Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 98. Combination Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 99. Combination Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 100. Combination Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 101. Combination Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 102. Fixed Dose Combinations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 103. Fixed Dose Combinations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 104. Fixed Dose Combinations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 105. Fixed Dose Combinations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 106. Fixed Dose Combinations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 107. Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 108. Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 109. Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 110. Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 111. Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 112. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 113. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 114. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 115. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 116. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 117. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 118. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 119. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 120. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 121. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 122. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 123. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 124. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 125. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 126. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 127. Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 128. Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 129. Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 130. Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 131. Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 132. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 133. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 134. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 135. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 136. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 137. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 138. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 139. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 140. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 141. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 142. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 143. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 144. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 145. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 146. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 147. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 148. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 149. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 150. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 151. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 152. Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 153. Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 154. Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 155. Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 156. Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 157. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 158. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 159. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 160. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 161. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 162. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 163. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 164. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 165. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 166. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 167. Ecommerce Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 168. Ecommerce Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 169. Ecommerce Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 170. Ecommerce Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 171. Ecommerce Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 172. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 173. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 174. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 175. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 176. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 177. North America Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 178. North America Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 179. North America Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 180. North America Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 181. North America Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 182. North America Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 183. North America Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 184. North America Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 185. North America Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 186. North America Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 187. North America Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 188. North America Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 189. North America Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 190. North America Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 191. North America Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 192. North America Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 193. North America Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 194. North America Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 195. North America Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 196. North America Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 197. North America Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 198. North America Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 199. North America Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 200. North America Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 201. North America Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 202. North America Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 203. North America Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 204. North America Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 205. North America Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 206. North America Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 207. North America Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 208. North America Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 209. North America Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 210. North America Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 211. North America Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 212. North America Antihypertensive Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 213. North America Antihypertensive Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 214. North America Antihypertensive Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 215. North America Antihypertensive Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 216. North America Antihypertensive Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 217. US Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 218. US Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 219. US Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 220. US Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 221. US Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 222. Canada Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 223. Canada Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 224. Canada Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 225. Canada Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 226. Canada Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 227. Europe Antihypertensive Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID) Table 82.
Table 228. Europe Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 229. Europe Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 230. Europe Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 231. Europe Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 232. Europe Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 233. Europe Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 234. Europe Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 235. Europe Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 236. Europe Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 237. Europe Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 238. Europe Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 239. Europe Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 240. Europe Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 241. Europe Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 242. Europe Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 243. Europe Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 244. Europe Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 245. Europe Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 246. Europe Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 247. Europe Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 248. Europe Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 249. Europe Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 250. Europe Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 251. Europe Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 252. Europe Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 253. Europe Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 254. Europe Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 255. Europe Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 256. Europe Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 257. Europe Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 258. Europe Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 259. Europe Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 260. Europe Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 261. Europe Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 262. Europe Antihypertensive Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 263. Europe Antihypertensive Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 264. Europe Antihypertensive Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 265. Europe Antihypertensive Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 266. UK Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 267. UK Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 268. UK Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 269. UK Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 270. UK Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 271. Germany Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 272. Germany Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 273. Germany Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 274. Germany Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 275. Germany Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 276. France Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 277. France Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 278. France Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 279. France Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 280. France Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 281. Rest of Europe Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 282. Rest of Europe Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 283. Rest of Europe Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 284. Rest of Europe Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 285. Rest of Europe Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 286. Asia Pacific Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 287. Asia Pacific Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 288. Asia Pacific Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 289. Asia Pacific Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 290. Asia Pacific Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 291. Asia Pacific Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 292. Asia Pacific Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 293. Asia Pacific Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 294. Asia Pacific Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 295. Asia Pacific Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 296. Asia Pacific Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 297. Asia Pacific Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 298. Asia Pacific Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 299. Asia Pacific Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 300. Asia Pacific Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 301. Asia Pacific Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 302. Asia Pacific Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 303. Asia Pacific Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 304. Asia Pacific Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 305. Asia Pacific Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 306. Asia Pacific Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 307. Asia Pacific Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 308. Asia Pacific Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 309. Asia Pacific Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 310. Asia Pacific Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 311. Asia Pacific Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 312. Asia Pacific Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 313. Asia Pacific Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 314. Asia Pacific Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 315. Asia Pacific Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 316. Asia Pacific Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 317. Asia Pacific Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 318. Asia Pacific Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 319. Asia Pacific Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 320. Asia Pacific Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 321. Asia Pacific Antihypertensive Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 322. Asia Pacific Antihypertensive Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 323. Asia Pacific Antihypertensive Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 324. Asia Pacific Antihypertensive Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 325. Asia Pacific Antihypertensive Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 326. China Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 327. China Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 328. China Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 329. China Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 330. China Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 331. India Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 332. India Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 333. India Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 334. India Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 335. India Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 336. Japan Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 337. Japan Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 338. Japan Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 339. Japan Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 340. Japan Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 341. RoAPAC Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 342. RoAPAC Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 343. RoAPAC Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 344. RoAPAC Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 345. RoAPAC Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 346. Middle East Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 347. Middle East Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 348. Middle East Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 349. Middle East Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 350. Middle East Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 351. Middle East Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 352. Middle East Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 353. Middle East Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 354. Middle East Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 355. Middle East Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 356. Middle East Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 357. Middle East Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 358. Middle East Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 359. Middle East Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 360. Middle East Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 361. Middle East Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 362. Middle East Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 363. Middle East Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 364. Middle East Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 365. Middle East Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 366. Middle East Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 367. Middle East Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 368. Middle East Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 369. Middle East Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 370. Middle East Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 371. Middle East Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 372. Middle East Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 373. Middle East Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 374. Middle East Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 375. Middle East Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 376. Middle East Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 377. Middle East Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 378. Middle East Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 379. Middle East Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 380. Middle East Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 381. Latin America Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 382. Latin America Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 383. Latin America Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 384. Latin America Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 385. Latin America Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 386. Latin America Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 387. Latin America Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 388. Latin America Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 389. Latin America Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 390. Latin America Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 391. Latin America Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 392. Latin America Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 393. Latin America Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 394. Latin America Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 395. Latin America Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 396. Latin America Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 397. Latin America Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 398. Latin America Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 399. Latin America Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 400. Latin America Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 401. Latin America Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 402. Latin America Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 403. Latin America Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 404. Latin America Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 405. Latin America Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 406. Latin America Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 407. Latin America Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 408. Latin America Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 409. Latin America Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 410. Latin America Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 411. Latin America Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 412. Latin America Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 413. Latin America Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 414. Latin America Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 415. Latin America Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 416. Africa Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 417. Africa Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 418. Africa Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 419. Africa Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 420. Africa Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 421. Africa Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 422. Africa Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 423. Africa Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 424. Africa Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 425. Africa Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 426. Africa Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 427. Africa Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 428. Africa Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 429. Africa Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 430. Africa Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 431. Africa Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 432. Africa Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 433. Africa Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 434. Africa Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 435. Africa Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 436. Africa Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 437. Africa Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 438. Africa Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 439. Africa Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 440. Africa Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 441. Africa Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 442. Africa Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 443. Africa Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 444. Africa Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 445. Africa Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 446. Africa Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 447. Africa Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 448. Africa Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 449. Africa Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 450. Africa Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 451. Leading 15 Antihypertensive Drugs Companies (Ranking, Company, Latest Total Company Sales US$M*, HQ)
Table 452. Pfizer Inc.Profile 2019 (CEO, HQ, Founded, Website)
Table 453. Pfizer Inc. Antihypertensive Drugs Product Offering (Segment, Product Offerings)
Table 454. Sanofi S.A Profile 2019 (CEO, HQ, Founded, Website)
Table 455. Sanofi S.A Antihypertensive Drugs Product Offering (Segment, Product Offerings)
Table 456. Novartis AG Profile 2019 (CEO, HQ, Founded, Website)
Table 457. Novartis AG.Antihypertensive Drugs Product Offering (Segment, Product Offerings)
Table 458. Boehringer Ingelheim GmbH Profile 2019 (CEO, HQ, Founded, Website)
Table 459. Boehringer Ingelheim GmbH Antihypertensive Drugs Product Offering (Segment, Product Offerings)
Table 460. Actelion Ltd. Profile 2019 (CEO, HQ, Founded, Website)
Table 461. Actelion Ltd. Antihypertensive Drugs Product Offering (Segment, Product Offerings)
Table 462. F. Hoffmann-La Roche Ltd. Profile 2019 (CEO, HQ, Founded, Website)
Table 463. F. Hoffmann-La Roche Ltd. Antihypertensive Drugs Product Offering (Segment, Product Offerings)
Table 464. Bayer AG Profile 2019 (CEO, HQ, Founded, Website)
Table 465. Bayer AG Antihypertensive Drugs Product Offering (Segment, Product Offerings)
Table 466. Glenmark Pharmaceutical Inc. Profile 2019 (CEO, HQ, Founded, Website)
Table 467. Glenmark Pharmaceutical Inc. Antihypertensive Drugs Product Offering (Segment, Product Offerings)
Table 468. Daiichi Sankyo Company, Limited Profile 2019 (CEO, HQ, Founded, Website)
Table 469. Daiichi Sankyo Company, Limited Antihypertensive Drugs Product Offering (Segment, Product Offerings)
Table 470. Takeda Pharmaceutical Company Limited Corporation Profile 2019 (CEO, HQ, Founded, Website)
Table 471. Takeda Pharmaceutical Company Limited Antihypertensive Drugs Product Offering (Segment, Product Offerings)
Table 472. AstraZeneca plc Corporation Profile 2019 (CEO, HQ, Founded, Website)
Table 473. AstraZeneca plc Antihypertensive Drugs Product Offering (Segment, Product Offerings)
Table 474. Johnson & Johnson Services, Inc.Corporation Profile 2019 (CEO, HQ, Founded, Website)
Table 475. Johnson & Johnson Services, Inc.Antihypertensive Drugs Product Offering (Segment, Product Offerings)
Table 476. Lupin Corporation Profile 2019 (CEO, HQ, Founded, Website)
Table 477. Lupin Antihypertensive Drugs Product Offering (Segment, Product Offerings)
Table 478. Merck & Co., Inc. Corporation Profile 2019 (CEO, HQ, Founded, Website)
Table 479. Merck & Co., Inc. .Antihypertensive Drugs Product Offering (Segment, Product Offerings)
Table 480. Sun Pharmaceutical Industries Ltd. Corporation Profile 2019 (CEO, HQ, Founded, Website)
Table 481. Sun Pharmaceutical Industries Ltd..Antihypertensive Drugs Product Offering (Segment, Product Offerings)
Table 482. Other Companies Involved in the Antihypertensive Drugs Market 2021 (Company, Location)
LIST OF FIGURES
Figure 1. Antihypertensive Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 2. Antihypertensive Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 3. Antihypertensive Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 4. Antihypertensive Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 5. Antihypertensive Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 6. Antihypertensive Drugs Market Drivers & Restraints 2021
Figure 7. Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 8. Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 9. Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 10. Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 11. Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 12. Diuretics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 13. Diuretics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 14. Diuretics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 15. Diuretics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 16. Diuretics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 17. Angiotensin Converting Enzyme Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 18. Angiotensin Converting Enzyme Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 19. Angiotensin Converting Enzyme Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 20. Angiotensin Converting Enzyme Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 21. Angiotensin Converting Enzyme Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 22. Angiotensin Receptor Blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 23. Angiotensin Receptor Blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 24. Angiotensin Receptor Blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 25. Angiotensin Receptor Blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 26. Angiotensin Receptor Blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 27. Beta-blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 28. Beta-blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 29. Beta-blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 30. Beta-blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 31. Beta-blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 32. Vasodilators Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 33. Vasodilators Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 34. Vasodilators Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 35. Vasodilators Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 36. Vasodilators Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 37. Calcium Channel Blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 38. Calcium Channel Blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 39. Calcium Channel Blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 40. Calcium Channel Blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 41. Calcium Channel Blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 42. Renin Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 43. Renin Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 44. Renin Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 45. Renin Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 46. Renin Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 47. Alpha-blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 48. Alpha-blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 49. Alpha-blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 50. Alpha-blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 51. Alpha-blockers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 52. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 53. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 54. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 55. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 56. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 57. Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 58. Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 59. Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 60. Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 61. Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 62. Primary Hypertension Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 63. Primary Hypertension Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 64. Primary Hypertension Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 65. Primary Hypertension Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 66. Primary Hypertension Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 67. Secondary Hypertension Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 68. Secondary Hypertension Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 69. Secondary Hypertension Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 70. Secondary Hypertension Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 71. Secondary Hypertension Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 72. Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 73. Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 74. Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 75. Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 76. Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 77. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 78. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 79. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 80. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 81. Generic Drugs h Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 82. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 83. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 84. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 85. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 86. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 87. Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 88. Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 89. Antihypertensive Drugs Market Forecast By Medication Type Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 90. Antihypertensive Drugs Market Forecast By Medication Type Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 91. Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 92. Monotherapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 93. Monotherapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 94. Monotherapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 95. Monotherapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 96. Monotherapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 97. Combination Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 98. Combination Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 99. Combination Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 100. Combination Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 101. Combination Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 102. Fixed Dose Combinations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 103. Fixed Dose Combinations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 104. Fixed Dose Combinations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 105. Fixed Dose Combinations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 106. Fixed Dose Combinations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 107. Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 108. Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 109. Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 110. Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 111. Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 112. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 113. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 114. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 115. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 116. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 117. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 118. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 119. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 120. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 121. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 122. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 123. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 124. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 125. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 126. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 127. Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 128. Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 129. Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 130. Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 131. Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 132. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 133. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 134. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 135. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 136. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 137. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 138. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 139. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 140. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 141. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 142. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 143. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 144. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 145. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 146. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 147. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 148. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 149. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 150. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 151. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 152. Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 153. Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 154. Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 155. Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 156. Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 157. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 158. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 159. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 160. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 161. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 162. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 163. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 164. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 165. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 166. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 167. Ecommerce Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 168. Ecommerce Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 169. Ecommerce Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 170. Ecommerce Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 171. Ecommerce Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 172. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 173. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 174. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 175. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 176. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 177. North America Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 178. North America Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 179. North America Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 180. North America Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 181. North America Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 182. North America Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 183. North America Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 184. North America Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 185. North America Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 186. North America Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 187. North America Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 188. North America Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 189. North America Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 190. North America Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 191. North America Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 192. North America Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 193. North America Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 194. North America Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 195. North America Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 196. North America Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 197. North America Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 198. North America Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 199. North America Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 200. North America Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 201. North America Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 202. North America Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 203. North America Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 204. North America Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 205. North America Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 206. North America Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 207. North America Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 208. North America Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 209. North America Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 210. North America Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 211. North America Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 212. North America Antihypertensive Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 213. North America Antihypertensive Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 214. North America Antihypertensive Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 215. North America Antihypertensive Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 216. North America Antihypertensive Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 217. US Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 218. US Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 219. US Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 220. US Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 221. US Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 222. Canada Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 223. Canada Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 224. Canada Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 225. Canada Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 226. Canada Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 227. Europe Antihypertensive Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID) Table 82.
Figure 228. Europe Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 229. Europe Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 230. Europe Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 231. Europe Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 232. Europe Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 233. Europe Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 234. Europe Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 235. Europe Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 236. Europe Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 237. Europe Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 238. Europe Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 239. Europe Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 240. Europe Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 241. Europe Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 242. Europe Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 243. Europe Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 244. Europe Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 245. Europe Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 246. Europe Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 247. Europe Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 248. Europe Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 249. Europe Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 250. Europe Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 251. Europe Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 252. Europe Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 253. Europe Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 254. Europe Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 255. Europe Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 256. Europe Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 257. Europe Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 258. Europe Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 259. Europe Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 260. Europe Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 261. Europe Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 262. Europe Antihypertensive Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 263. Europe Antihypertensive Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 264. Europe Antihypertensive Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 265. Europe Antihypertensive Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 266. UK Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 267. UK Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 268. UK Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 269. UK Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 270. UK Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 271. Germany Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 272. Germany Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 273. Germany Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 274. Germany Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 275. Germany Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 276. France Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 277. France Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 278. France Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 279. France Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 280. France Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 281. Rest of Europe Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 282. Rest of Europe Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 283. Rest of Europe Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 284. Rest of Europe Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 285. Rest of Europe Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 286. Asia Pacific Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 287. Asia Pacific Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 288. Asia Pacific Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 289. Asia Pacific Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 290. Asia Pacific Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 291. Asia Pacific Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 292. Asia Pacific Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 293. Asia Pacific Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 294. Asia Pacific Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 295. Asia Pacific Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 296. Asia Pacific Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 297. Asia Pacific Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 298. Asia Pacific Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 299. Asia Pacific Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 300. Asia Pacific Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 301. Asia Pacific Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 302. Asia Pacific Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 303. Asia Pacific Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 304. Asia Pacific Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 305. Asia Pacific Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 306. Asia Pacific Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 307. Asia Pacific Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 308. Asia Pacific Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 309. Asia Pacific Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 310. Asia Pacific Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 311. Asia Pacific Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 312. Asia Pacific Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 313. Asia Pacific Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 314. Asia Pacific Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 315. Asia Pacific Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 316. Asia Pacific Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 317. Asia Pacific Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 318. Asia Pacific Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 319. Asia Pacific Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 320. Asia Pacific Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 321. Asia Pacific Antihypertensive Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 322. Asia Pacific Antihypertensive Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 323. Asia Pacific Antihypertensive Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 324. Asia Pacific Antihypertensive Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 325. Asia Pacific Antihypertensive Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 326. China Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 327. China Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 328. China Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 329. China Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 330. China Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 331. India Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 332. India Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 333. India Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 334. India Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 335. India Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 336. Japan Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 337. Japan Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 338. Japan Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 339. Japan Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 340. Japan Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 341. RoAPAC Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 342. RoAPAC Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 343. RoAPAC Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 344. RoAPAC Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 345. RoAPAC Antihypertensive Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 346. Middle East Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 347. Middle East Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 348. Middle East Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 349. Middle East Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 350. Middle East Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 351. Middle East Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 352. Middle East Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 353. Middle East Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 354. Middle East Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 355. Middle East Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 356. Middle East Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 357. Middle East Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 358. Middle East Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 359. Middle East Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 360. Middle East Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 361. Middle East Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 362. Middle East Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 363. Middle East Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 364. Middle East Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 365. Middle East Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 366. Middle East Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 367. Middle East Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 368. Middle East Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 369. Middle East Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 370. Middle East Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 371. Middle East Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 372. Middle East Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 373. Middle East Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 374. Middle East Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 375. Middle East Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 376. Middle East Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 377. Middle East Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 378. Middle East Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 379. Middle East Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 380. Middle East Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 381. Latin America Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 382. Latin America Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 383. Latin America Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 384. Latin America Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 385. Latin America Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 386. Latin America Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 387. Latin America Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 388. Latin America Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 389. Latin America Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 390. Latin America Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 391. Latin America Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 392. Latin America Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 393. Latin America Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 394. Latin America Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 395. Latin America Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 396. Latin America Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 397. Latin America Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 398. Latin America Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 399. Latin America Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 400. Latin America Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 401. Latin America Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 402. Latin America Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 403. Latin America Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 404. Latin America Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 405. Latin America Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 406. Latin America Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 407. Latin America Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 408. Latin America Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 409. Latin America Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 410. Latin America Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 411. Latin America Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 412. Latin America Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 413. Latin America Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 414. Latin America Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 415. Latin America Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 416. Africa Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 417. Africa Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 418. Africa Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 419. Africa Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 420. Africa Antihypertensive Drugs Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 421. Africa Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 422. Africa Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 423. Africa Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 424. Africa Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 425. Africa Antihypertensive Drugs Market Forecast By Condition 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 426. Africa Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 427. Africa Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 428. Africa Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 429. Africa Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 430. Africa Antihypertensive Drugs Market Forecast By Medication Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 431. Africa Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 432. Africa Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 433. Africa Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 434. Africa Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 435. Africa Antihypertensive Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 436. Africa Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 437. Africa Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 438. Africa Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 439. Africa Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 440. Africa Antihypertensive Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 441. Africa Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 442. Africa Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 443. Africa Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 444. Africa Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 445. Africa Antihypertensive Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 446. Africa Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 447. Africa Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 448. Africa Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 449. Africa Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 450. Africa Antihypertensive Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 451. Leading 15 Antihypertensive Drugs Companies (Ranking, Company, Latest Total Company Sales US$M*, HQ)
Figure 452. Pfizer Inc.Profile 2019 (CEO, HQ, Founded, Website)
Figure 453. Pfizer Inc. Antihypertensive Drugs Product Offering (Segment, Product Offerings)
Figure 454. Sanofi S.A Profile 2019 (CEO, HQ, Founded, Website)
Figure 455. Sanofi S.A Antihypertensive Drugs Product Offering (Segment, Product Offerings)
Figure 456. Novartis AG Profile 2019 (CEO, HQ, Founded, Website)
Figure 457. Novartis AG.Antihypertensive Drugs Product Offering (Segment, Product Offerings)
Figure 458. Boehringer Ingelheim GmbH Profile 2019 (CEO, HQ, Founded, Website)
Figure 459. Boehringer Ingelheim GmbH Antihypertensive Drugs Product Offering (Segment, Product Offerings)
Figure 460. Actelion Ltd. Profile 2019 (CEO, HQ, Founded, Website)
Figure 461. Actelion Ltd. Antihypertensive Drugs Product Offering (Segment, Product Offerings)
Figure 462. F. Hoffmann-La Roche Ltd. Profile 2019 (CEO, HQ, Founded, Website)
Figure 463. F. Hoffmann-La Roche Ltd. Antihypertensive Drugs Product Offering (Segment, Product Offerings)
Figure 464. Bayer AG Profile 2019 (CEO, HQ, Founded, Website)
Figure 465. Bayer AG Antihypertensive Drugs Product Offering (Segment, Product Offerings)
Figure 466. Glenmark Pharmaceutical Inc. Profile 2019 (CEO, HQ, Founded, Website)
Figure 467. Glenmark Pharmaceutical Inc. Antihypertensive Drugs Product Offering (Segment, Product Offerings)
Figure 468. Daiichi Sankyo Company, Limited Profile 2019 (CEO, HQ, Founded, Website)
Figure 469. Daiichi Sankyo Company, Limited Antihypertensive Drugs Product Offering (Segment, Product Offerings)
Figure 470. Takeda Pharmaceutical Company Limited Corporation Profile 2019 (CEO, HQ, Founded, Website)
Figure 471. Takeda Pharmaceutical Company Limited Antihypertensive Drugs Product Offering (Segment, Product Offerings)
Figure 472. AstraZeneca plc Corporation Profile 2019 (CEO, HQ, Founded, Website)
Figure 473. AstraZeneca plc Antihypertensive Drugs Product Offering (Segment, Product Offerings)
Figure 474. Johnson & Johnson Services, Inc.Corporation Profile 2019 (CEO, HQ, Founded, Website)
Figure 475. Johnson & Johnson Services, Inc.Antihypertensive Drugs Product Offering (Segment, Product Offerings)
Figure 476. Lupin Corporation Profile 2019 (CEO, HQ, Founded, Website)
Figure 477. Lupin Antihypertensive Drugs Product Offering (Segment, Product Offerings)
Figure 478. Merck & Co., Inc. Corporation Profile 2019 (CEO, HQ, Founded, Website)
Figure 479. Merck & Co., Inc. .Antihypertensive Drugs Product Offering (Segment, Product Offerings)
Figure 480. Sun Pharmaceutical Industries Ltd. Corporation Profile 2019 (CEO, HQ, Founded, Website)
Figure 481. Sun Pharmaceutical Industries Ltd..Antihypertensive Drugs Product Offering (Segment, Product Offerings)
Figure 482. Other Companies Involved in the Antihypertensive Drugs Market 2021 (Company, Location)
Figure 483. Porter’s Five Force Analysis
Companies Profiled in the Report
1. Pfizer Inc.
2. Sanofi S.A
3. Novartis AG
4. Boehringer Ingelheim GmbH
5. Actelion Ltd.
6. F. Hoffmann-La Roche Ltd.
7. Bayer AG
8. Glenmark Pharmaceutical Inc.
9. Daiichi Sankyo Company, Limited
10. Takeda Pharmaceutical Company Limited
11. AstraZeneca plc
12. Johnson & Johnson Services, Inc.
13. Lupin
14. Merck & Co., Inc.
15. Sun Pharmaceutical Industries Ltd.
List of Companies Mentioned in the Report:
1. Johnson & Johnson
2. Pfizer Inc
3. Roche Holding AG
4. Novartis AG
5. Merck & Co Inc
6. Sanofi SA
7. AbbVie Inc
8. Bristol-Myers Squibb Co
9. GlaxoSmithKline PLC
10. Bayer AG
11. Eli Lilly and Co
12. Allergan plc
13. Novo Nordisk A/S
14. AstraZeneca PLC
15. Biogen Inc
16. Abbott Laboratories
17. Shire PLC
18. Teva Pharmaceutical Industries Ltd
19. CSL Ltd
20. Takeda Pharmaceutical Co Ltd
21. Astellas Pharma Inc
22. Alexion Pharmaceuticals Inc
23. Zoetis Inc
24. Otsuka Holdings Co Ltd
25. MYL.O
26. Eisai Co Ltd
27. Shionogi & Co Ltd
28. Chugai Pharmaceutical Co Ltd
29. Jiangsu Hengrui Medicine Co Ltd
30. Biomarin Pharmaceutical Inc
31. Daiichi Sankyo Co Ltd
32. Merck KGaA
33. Ono Pharmaceutical Co Ltd
34. Kangmei Pharmaceutical Co Ltd
35. Grifols SA
36. UCB SA
37. Perrigo Company PLC
38. Mitsubishi Tanabe Pharma Corp
39. Shanghai Fosun Pharmaceutical Group Co Ltd
40. Kyowa Hakko Kirin Co Ltd
41. Taisho Pharmaceutical Holdings Co Ltd
42. Jazz Pharmaceuticals PLC
43. Sumitomo Dainippon Pharma Co Ltd
44. China Grand Automotive Services Co Ltd
45. Tasly Pharmaceutical Group Co Ltd
46. Orion Oyj
47. CSPC Pharmaceutical Group Ltd
48. Beijing Tongrentang Co Ltd
49. Ipsen SA
50. Recordati Industria Chimica e Farmaceutica SpA
List of Organizations Mentioned in the Report:
1. Center for Drug Evaluation and Research (CDER)
2. Agência Nacional de Vigilância Sanitária (ANVISA)
3. European Medicines Agency (EMA)
4. Food and Drug Administration (FDA)
5. Ministry of Health, Labour and Welfare (MHLW)
6. Michigan State University
7. National Institute for Health and Clinical Excellence (NICE)
8. National Institutes of Health (NIH)
9. University of Connecticut
10. World Health Organization (WHO)
11. The National Medical Products Administration (NMPA)
12. Indian Council of Medical Research (ICMR)
13. The Therapeutic Goods Administration
14. The Federal Institute for Drugs and Medical Devices (BfArM)
15. Pharmaceuticals and Medical Devices Agency (PMDA)
16. Agencia Nacional de Vigiloncia Sanitaria (ANVISA )
17. Ministry of Health, Labour & Welfare(MHLW)
18. Medicines and Healthcare Products Regulatory Agency (MHRA)
19. Centre for Pharmaceutical Administration Health Sciences Authority
20. Central Drug Standard Control Organization (CDSCO)
1. Pfizer Inc.
2. Sanofi S.A
3. Novartis AG
4. Boehringer Ingelheim GmbH
5. Actelion Ltd.
6. F. Hoffmann-La Roche Ltd.
7. Bayer AG
8. Glenmark Pharmaceutical Inc.
9. Daiichi Sankyo Company, Limited
10. Takeda Pharmaceutical Company Limited
11. AstraZeneca plc
12. Johnson & Johnson Services, Inc.
13. Lupin
14. Merck & Co., Inc.
15. Sun Pharmaceutical Industries Ltd.
List of Companies Mentioned in the Report:
1. Johnson & Johnson
2. Pfizer Inc
3. Roche Holding AG
4. Novartis AG
5. Merck & Co Inc
6. Sanofi SA
7. AbbVie Inc
8. Bristol-Myers Squibb Co
9. GlaxoSmithKline PLC
10. Bayer AG
11. Eli Lilly and Co
12. Allergan plc
13. Novo Nordisk A/S
14. AstraZeneca PLC
15. Biogen Inc
16. Abbott Laboratories
17. Shire PLC
18. Teva Pharmaceutical Industries Ltd
19. CSL Ltd
20. Takeda Pharmaceutical Co Ltd
21. Astellas Pharma Inc
22. Alexion Pharmaceuticals Inc
23. Zoetis Inc
24. Otsuka Holdings Co Ltd
25. MYL.O
26. Eisai Co Ltd
27. Shionogi & Co Ltd
28. Chugai Pharmaceutical Co Ltd
29. Jiangsu Hengrui Medicine Co Ltd
30. Biomarin Pharmaceutical Inc
31. Daiichi Sankyo Co Ltd
32. Merck KGaA
33. Ono Pharmaceutical Co Ltd
34. Kangmei Pharmaceutical Co Ltd
35. Grifols SA
36. UCB SA
37. Perrigo Company PLC
38. Mitsubishi Tanabe Pharma Corp
39. Shanghai Fosun Pharmaceutical Group Co Ltd
40. Kyowa Hakko Kirin Co Ltd
41. Taisho Pharmaceutical Holdings Co Ltd
42. Jazz Pharmaceuticals PLC
43. Sumitomo Dainippon Pharma Co Ltd
44. China Grand Automotive Services Co Ltd
45. Tasly Pharmaceutical Group Co Ltd
46. Orion Oyj
47. CSPC Pharmaceutical Group Ltd
48. Beijing Tongrentang Co Ltd
49. Ipsen SA
50. Recordati Industria Chimica e Farmaceutica SpA
List of Organizations Mentioned in the Report:
1. Center for Drug Evaluation and Research (CDER)
2. Agência Nacional de Vigilância Sanitária (ANVISA)
3. European Medicines Agency (EMA)
4. Food and Drug Administration (FDA)
5. Ministry of Health, Labour and Welfare (MHLW)
6. Michigan State University
7. National Institute for Health and Clinical Excellence (NICE)
8. National Institutes of Health (NIH)
9. University of Connecticut
10. World Health Organization (WHO)
11. The National Medical Products Administration (NMPA)
12. Indian Council of Medical Research (ICMR)
13. The Therapeutic Goods Administration
14. The Federal Institute for Drugs and Medical Devices (BfArM)
15. Pharmaceuticals and Medical Devices Agency (PMDA)
16. Agencia Nacional de Vigiloncia Sanitaria (ANVISA )
17. Ministry of Health, Labour & Welfare(MHLW)
18. Medicines and Healthcare Products Regulatory Agency (MHRA)
19. Centre for Pharmaceutical Administration Health Sciences Authority
20. Central Drug Standard Control Organization (CDSCO)
Download sample pages
Complete the form below to download your free sample pages for Antihypertensive Drugs Market Report 2021-2031Related reports
-
Electrostatic Discharge (ESD) Packaging Market Report 2020-2030
Electrostatic discharge packaging helps in shielding electronic equipment’s and employs special packaging that helps in decreasing the accumulation of electrical...
Full DetailsPublished: 01 January 1970 -
Antibacterial Drugs Market Report 2021-2031
The prevalence of bacterial diseases is significantly growing and expected to continuously rise over the forecast period. Number of bacterial...Full DetailsPublished: 01 January 1970 -
Global MV Protection Relay Market Report 2019-2029
There have been a considerable number of product launches, product developments, mergers, and acquisitions recently in the global MV Protection...
Full DetailsPublished: 01 January 1970 -
X-ray Systems Market Forecast 2020-2030
A complete analysis of the business models, core strategies and respective market shares of some of the most important players...Full DetailsPublished: 01 January 1970 -
Volumetric Display Market Report 2019-2029
The global Volumetric Display market is expected to grow at a lucrative rate during the forecast period.
...Full DetailsPublished: 01 January 1970 -
Static Compensator Market Report 2021-2031
In recent years, battery energy storage (BES) techniques are fast developing due to the advancement of power electronics and battery...Full DetailsPublished: 15 February 2021 -
Cholesterol Lowering Drugs Market Report 2021-2031
Increasing risk of high cholesterol and associated diseases has lead various leading drug manufactures to increase their research and development...Full DetailsPublished: 01 January 1970 -
Non-alcoholic Fatty Liver Disease (NAFLD) & NASH Market Report 2021-2031
The report study aims to explore the market drivers, restraints and also market opportunities facing non-alcoholic fatty liver disease &...Full DetailsPublished: 17 February 2021 -
Drugs of Abuse Testing Market Report 2021-2031
Drugs Abuse has risen very significantly in few last year as compared to previous once and expected to continuously rise...Full DetailsPublished: 01 January 1970
Download sample pages
Complete the form below to download your free sample pages for Antihypertensive Drugs Market Report 2021-2031Do you have any custom requirements we can help you with?
Any specific country, geo region, market segment or specific company information?
Email us today, we can discuss your needs and see how we can help: jamie.roberts@visiongain.com
Would you like a free report overview of the report of your choice?
If so, please drop an email to Jamie Roberts stating your chosen report title to jamie.roberts@visiongain.com
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email jamie.roberts@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.”
Dr Luz Chapa Azuella, Mexico
American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia
Visiongain Pharma
Visiongain Pharma
Visiongain PharmaLatest Pharma news
Visiongain Publishes Drug Delivery Technologies Market Report 2024-2034
The global Drug Delivery Technologies market is estimated at US$1,729.6 billion in 2024 and is projected to grow at a CAGR of 5.5% during the forecast period 2024-2034.
23 April 2024
Visiongain Publishes Cell Therapy Technologies Market Report 2024-2034
The cell therapy technologies market is estimated at US$7,041.3 million in 2024 and is projected to grow at a CAGR of 10.7% during the forecast period 2024-2034.
18 April 2024
Visiongain Publishes Automation in Biopharma Industry Market Report 2024-2034
The global Automation in Biopharma Industry market is estimated at US$1,954.3 million in 2024 and is projected to grow at a CAGR of 7% during the forecast period 2024-2034.
17 April 2024
Visiongain Publishes Anti-obesity Drugs Market Report 2024-2034
The global Anti-obesity Drugs market is estimated at US$11,540.2 million in 2024 and is expected to register a CAGR of 21.2% from 2024 to 2034.
12 April 2024
